



**The Association for
Clinical Biochemistry &
Laboratory Medicine**

Better Science, Better Testing, Better Care



ANNUAL REPORT AND ACCOUNTS

YEAR ENDING 31 DECEMBER 2019



Images:
Top: The Tall Ship, Glasgow
Above left: The 2019 Clinical Case presenters with
Dr Danielle Freedman and Dr Kevin Deans at
Focus 2019 in Glasgow

Image on page 6
© Lancashire Teaching Hospitals

CONTENTS

Mission statement	2
President's foreword	4
Chief Executive Officer's report	5
Education, Training and Workforce Committee	6
Scientific Committee	7
Publications & Communications Committee	8
National Meetings Committee	9
Microbiology Professional Committee	10
Immunology Professional Committee	11
ACB around the UK and Ireland	12
Federation of Clinical Scientists	14
Equality, Diversity & Inclusion Statement	15
Awards, funds and prizes	16
Director of Finance's Report	18
Accounts – Report & Financial Statements	19
Accounts – Benevolent Fund	29
Accounts – C.P. Stewart Memorial Fund	34
Accounts – Clinical Biochemistry Conferences	40
Acknowledgements	46

MISSION STATEMENT

The Association for Clinical Biochemistry and Laboratory Medicine (ACB) is a professional body dedicated to the practice and promotion of Clinical Biochemistry, Immunology and Microbiology in the UK.

The ACB provides:

- ◆ Training
- ◆ Professional leadership
- ◆ Best practice and guidance to the profession, governments, public and media.

The ACB liaises with, and is consulted by, national and international organisations on issues relating to Clinical Biochemistry, Immunology and Microbiology.

Founded in 1953, the ACB has medical and non-medical Members in all major UK healthcare laboratories, in many university departments and in several commercial companies involved in healthcare.

The links with its Corporate Members lead to a fruitful relationship with the Clinical Diagnostics industry.


The ACB's Federation of Clinical Scientists provides the only Trade Union support for Clinical Scientists run by Clinical Scientists.

LOOKING FORWARD 2020/2021

- ◆ Improved database and website to provide a better service to the membership.
- ◆ New five year strategy to streamline and strengthen our service to the membership and what ACB stands for nationally and internationally.

2019 AT A GLANCE

72% survey respondents rated ACB the same or better than other associations



Results from 2019 ACB membership survey

INVESTING TO IMPROVE SERVICE



Chief Executive Officer for strategic oversight of ACB



Professional conference organisers for smooth running of meetings and conferences



Communications support to improve communication with the membership



New ACB Office IT hardware to provide a reliable and secure service

ENGAGING OUR COMMUNITY



6 ACB News magazine issues published



1 approved Equality, Diversity and Inclusion Strategy



2042 ACB members

FOSTERING THE NEXT GENERATION



4 National Training Days



£36,700 awarded in Scientific Scholarships to six emerging Clinical Scientists

PROMOTED CUTTING-EDGE RESEARCH



2 international conferences




5 reviews commissioned by Clinical Sciences Review Committee published



in *Annals of Clinical Biochemistry* journal article downloads compared to 2018 (2018 - 597,940; 2019 - 735,466)

PROVIDING BEST PRACTICE GUIDANCE AND INFORMATION



121 NICE outputs reviewed on clinical guidance, diagnostics guidance, technical assessments

3.7 million website visits

to the public information website **Lab Tests Online-UK** in 2019

PRESIDENT'S FOREWORD



'In July 2019, Council convened to reaffirm our strategic ambitions to be the pre-eminent clinical organisation for laboratory medicine in the UK, to promote research and innovation for better patient care and to promote the importance of laboratory medicine to the wider community.'

I started my term as ACB President in May 2019 with an ambition to build on the hard work of my predecessors to bring the voice of diagnostics within the clinical pathway to the fore.

In July, Council convened to reaffirm our strategic ambitions to be the pre-eminent clinical organisation for laboratory medicine in the UK, to promote research and innovation for better patient care and to promote the importance of laboratory medicine to the wider community. In doing so it is a necessity to meet the educational and professional needs of our membership, growing our influence and global network, whilst running a financially healthy and efficient organisation.

We surveyed the membership in Autumn and learned that 72% of Members rate ACB as the same or better than other associations – a good base to build from but clearly lots of opportunity to do more. We will use all of the feedback to learn and improve on the services to members and the influence the ACB has in the wider healthcare setting. One area we have already started in is the improvements to the ACB website; this is underpinned by a flexible membership database and will lead to a site that is used by Members and of use to the general public.

Of our activities *ACB News* continues to be highly valued by members and in these challenging times has been a vital resource for all ACB Members. Our National and regional meetings, including Focus and FiLM, and our education and training workshops continue to receive both recognition and praise for their scientific content and their networking opportunities.

Our digital presence increased with introduction of rapid publication of biochemical research through our official journal *Annals of Clinical Biochemistry* and our consumer facing site Lab Tests Online increased its average hit rate by 83% and attracted over 3.7 million web visits.

2019 saw a year of renewed vigour for the Microbiology and Immunology Professional Committees across training, audits, clinical reviews and specialist guidance, all underpinned by a closer working relationship with the ACB staff team.

2019 also marked the start of a period of investment for the future. The appointment of an interim CEO for the second half of the year allowed us to bring in professional conference organisers to improve the delivery of our National Meetings and conferences, recruit a communications consultant to support membership engagement and, at the end of the year, appoint our first permanent CEO to drive the growth and development of the ACB.

As I write this, we are in the throes of the COVID-19 pandemic. Whilst this is having an immediate impact on the activities and operations of the ACB in 2020 and beyond, I know that we are resilient and resourceful and that our financial position is stable in the long term.

My congratulations go to the recipients of the scientific and education awards; it is only by the ACB investing in these innovators that the profession as a whole grows and develops. Also, to Rachael Wilmot who was awarded the President's Shield for her excellent work on the ACB Equality, Diversity and Inclusion Strategy. I would like to offer my sincere thanks to ACB Members who tirelessly give up their time to serve on regional and National ACB committees: the Association is strong through the expertise you bring.

Finally, and most importantly, I am immensely proud of the way ACB Members have stepped up to the challenge of COVID-19: you have made the case for Pathology to lead through demonstrating that 'Better Science, Better Testing and Better Care' adds value and improves patient care.

Professor Neil Anderson

CHIEF EXECUTIVE OFFICER'S REPORT

I was delighted to join the ACB as your first permanent CEO in November 2019 as the year was coming to a close.

I attended my first Council Meeting three days after joining, where I was hugely impressed by the commitment and dedication of the officers who give so much of their own time to support the Members and drive the organisation forward.

Much thinking and preparation had already taken place in advance of my arrival, co-ordinated by interim CEO Sue Thorn under Neil Anderson's leadership, and now we are taking that work forward to build a sustainable, innovative and forward-thinking organisation that is the pre-eminent membership organisation for laboratory medicine.

'The impact of the COVID pandemic cannot be overstated in terms of ... public interest in ACB Members' work. We will now build on that to ensure the ACB is a strong and credible advocate for the best science and the best scientists.'

Of some urgency is getting our infrastructure up to date and fit for purpose, including our staff resourcing.

We are well on the way with that work with a revised team structure, upgraded IT and software, and a new website in the pipeline.

We look forward to unveiling this work over the next few months.

And, of course, the impact of the COVID pandemic cannot be overstated in terms of the profile of ACB Members' work and the pressure that it has put on the ACB operations and officers. It has highlighted gaps in our structures but, at the same time, given us the drive to address those gaps at pace. It has also provided a platform of unimagined public interest in our work. We will now build on that to raise ACB's profile and strengthen our voice.

The pandemic has also meant a rethink of our events programme and the difficult decision to postpone Focus 2020 in Belfast to March 2021. I look forward to meeting more ACB Members in person over the next year as we gradually rebuild our events programme in line with official advice and adopting new technologies to broaden their reach.

It's been a most unexpected first six months but it's been a privilege to support ACB Members as you continue to step up to this challenge.

I am looking forward to where 2020 will take us.

Jane Pritchard



'I attended my first Council meeting three days after joining, where I was hugely impressed by the commitment and dedication of the officers who give so much of their own time to support the Members and drive the organisation forward.'

EDUCATION, TRAINING AND WORKFORCE COMMITTEE

Supports the promotion and delivery of training for Clinical Biochemists at all stages of their careers. Provides a co-ordinated programme of training courses, and organises and monitors in-service training through a network of regional tutors. Monitors and co-ordinates manpower planning for the profession.

Director: Hazel Borthwick



Professional training programmes

This year, the Committee organised a number of training events for our members as well as supporting the National School of Healthcare Science during the Scientist Training Programme and Higher Specialist Scientific Training Programme recruitment rounds and the Objective Structured Final Assessments. The Committee continues to engage with the Royal College of Pathologists and has increased its engagement with the ACB Immunology and Microbiology Professional Committees.

National training day: science communication and inter-disciplinary care

The Committee organised another successful training day this year, preceding the national Focus meeting held in Glasgow with over sixty delegates. The morning session, delivered by Sense About Science, was an interactive session where delegates discussed how misrepresentation of science and evidence can impact the public and healthcare profession. The afternoon session focussed on the roles of Immunologists and Biochemists, cross-discipline cases and how multi-disciplinary working benefits patient care.

Statistics Training Day

As part of organising training for the wider membership the Committee organised a Statistics Training Day which specifically targeted day to day statistics that laboratories use, through simple, relevant examples. The course was oversubscribed and will be repeated in 2020 to enable more of the membership to attend.

Electives day and welcoming Trainees to ACB

The Trainee sub-group hosted a successful electives day in 2019. The Committee also represented ACB at the

Scientific Training Programme induction event to encourage new Trainees to become ACB Members.

Regional tutors

Our regional tutors have continued to be a source of knowledge and advice to our pre-registration membership, have organised many regional training events and annual assessments and participated in Objective Structured Final Assessment examinations.

Funding for Scientist Training Programme

The Committee raised concerns over the future funding for the Scientist Training Programme, which along with the collective professional body opinion resulted in securing appropriate funding. This means we can continue to attract high-calibre scientists into the profession.

Clinical Scientist Apprenticeship Standard

The Committee has also been involved in the development of the draft Clinical Scientist Apprenticeship Standard, which will enable some specialist areas of the profession to use a more appropriate and specific recruitment process to improve workforce planning.

'Over 60 delegates attended the 2019 ACB National Training Day on science communication and multi-disciplinary care'

LOOKING FORWARD

2020/2021

- ◆ Committee sub-group to focus on e-learning and sharing educational material across the membership, and on offering more training for post-registration members.
- ◆ Statistics Training Day to be offered in 2020.
- ◆ Committee to significantly overhaul the Education and Trainee sections of the website and update it with more educational content.
- ◆ Host a Higher Specialist Scientist Training/Fellow of the Royal College of Pathologists (FRCPath) Part 2 Project day or afternoon.
- ◆ Continue to organise the National ACB Training and Management Courses.
- ◆ Promote storing of regional educational material on the ACB website.

SCIENTIFIC COMMITTEE

Responds on behalf of the ACB on all scientific matters of relevance to the practice of clinical biochemistry.

Director: Alexandra Yates

It has been a successful year for the newly merged Scientific Committee and Clinical Practice Section.

ACB Scientific Scholarships

Reviewing and awarding the annual Scholarships is always enjoyable; it is inspiring to see the interesting work being carried out by members.

All eleven applications received in 2019 were of a high standard and, unlike previous years, were only submitted by ACB Members with biochemistry backgrounds. Due to the high standard of applications five rather than the usual three projects were fully funded (see Awards on pages 16 and 17).

'The high standard of ACB Scientific Scholarship applications resulted in the Committee funding six rather than the usual three projects'

NICE engagement and the Accelerated Access Collaborative

The Committee's ongoing success engaging with NICE was strengthened in 2019. Our sub-committees tirelessly reviewed 122 NICE outputs in 2019, concentrating on clinical guidance, diagnostics guidance and technical assessments. This year thirteen ACB Members, with the help of the ACB NICE Sub-Committee, have had a role in the production of NICE guidance. A standing member of the Committee is also on the NICE Diagnostic Advisor Committee and continues to serve as a link between this group and the ACB.

In 2019, NICE launched the Accelerated Access Collaborative initiative to make the NHS one of the most pro-innovation health systems in the world. NICE sought advice from the ACB on how to promote this scheme to the wider membership and how the ACB's views can be taken into account in future schemes. This is an exciting development and will allow the ACB to play a pivotal role in translation laboratory medicine.

Clinical Sciences Reviews Committee

The Clinical Sciences Reviews Committee (CSRC) is a sub-committee of the Scientific Committee responsible for the commissioning of reviews, commentaries, personal views or point versus counterpoint arguments on any aspect of clinical biochemistry and laboratory medicine.

Five reviews commissioned by CSRC were published in 2019:

- ◆ P Wainwright & P Cook. Assessment of iodine status – populations, individuals and limitations. *Ann Clin Biochem* 2019; 56: 7-14.
- ◆ A Viljoen, R Chaudhry & J Bycroft. Renal stones. *Ann Clin Biochem* 2019; 56: 15-27.
- ◆ JG Sanchez-Hernandez, N Rebollo, F Munoz, A Martin-Suarez & MV Calvo. Therapeutic drug monitoring of tumour necrosis factor inhibitors in the management of chronic inflammatory diseases. *Ann Clin Biochem* 2019; 56: 28-41.
- ◆ SL Jones, B Campbell & T Hart. Laboratory tests commonly used in complementary and alternative medicine: a review of the evidence. *Ann Clin Biochem* 2019; 56: 310-325.
- ◆ G Avery. Biotin interference in immunoassay: A review for the laboratory scientist. *Ann Clin Biochem* 2019; 56: 424-430.

In addition, the committee are pursuing twenty-three active reviews and have twenty-eight proposals under consideration.

National Audit Group

The 2019 National Audit meeting was held at the fantastic surroundings of the new Royal College of Pathologists. Seventy delegates attended the oversubscribed meeting. The morning session was a thought-provoking series of talks and discussion including the results of the national audit around hyperammonaemia. The afternoon session focussed on pheochromocytoma and paraganglioma, with results of the national audit and clinical aspects discussed.

LOOKING FORWARD

2020/2021

- ◆ Continue to work for members in scientific and clinical matters of interest, from local queries to international guidelines.
- ◆ Relaunch the Analyte Monologues (AMALCs) to publicise an external resource for clinical colleagues.
- ◆ Recruit authors across all disciplines for the AMALCs relaunch.
- ◆ National Audit Group meeting 2020.
- ◆ National audits for 2020:
 - Sweat testing for the investigation of cystic fibrosis
 - B-type natriuretic peptide
 - Faecal immunochemical testing.
- ◆ Increased contribution to Science Communication to ensure that information in the public domain relating to the laboratory diagnosis of infectious diseases is accurate.

PUBLICATIONS AND COMMUNICATIONS COMMITTEE

Oversees all communication from the ACB to its membership and the public.

Director: Kam Chatha

Membership survey and website

The high response rate to the survey – 20% of the membership – gave ACB useful feedback for improving services to the membership. Respondents rated *Annals of Clinical Biochemistry* and *ACB News* magazine the top two highest quality membership benefits. While the website was rated the top most important member benefit, it was also rated one of the lowest quality benefits. In 2019, the Committee worked with all ACB committees to create a website brief and specification with a view to creating a new website, content management system and membership-only online area in 2020.

Annals of Clinical Biochemistry: ACB's official journal

'Online First' and 'Annals Express' are helping with rapid publication of biochemical research, with all but the current and previous volumes open access. The number of downloads has risen and is on course to reach 600,000 in 2020. The impact factor for 2018 was 1.893, fractionally lower than previous years. The significance of this downwards trend is unclear, particularly when other citation metrics over the same period, such as a high score in the immediacy index and stable ranking in 'Medical Laboratory Technology' journals, are taken into account.

The shorter timescales to first and final editorial decisions are thanks to the collective effort of our responsive and committed editorial team. The number of manuscript submissions has dropped since 2018 and a significant number of articles are rejected without peer review, based on editorial decisions on their likelihood of acceptance. Research articles made up 78% of submitted papers. We continue to work closely with the Clinical Sciences Reviews Committee.

ACB News Magazine: Keeping our membership up-to-date

Submissions for our two-monthly *ACB News* magazine are increasing. Liaising with the ACB office team has helped *ACB News* content to be as up-to-date as possible. The packaging previously used for postage was replaced with a more eco-friendly option and has been well received by the membership.

Lab Tests Online-UK

The website was well used in 2019 with an average hit rate of 307,000 sessions per month, an 83% increase on 2018 and a jump mostly thanks to structural changes to the new website. In 2019, Lab Tests Online-UK was adopted in countries across the world, including Australia, China, South Korea, Brazil and Turkey. In 2019, the American Association for Clinical Chemistry won several awards and accolades for Lab Tests Online content and the new website design, including the AVA Digital Award recognising excellence by creative professionals. Lab Tests Online-UK celebrated its 15th Anniversary at Focus in May 2019.

Lab Tests Online-UK is a website providing patients and carers with accessible information on clinical laboratory tests. Lab Tests Online-UK has no commercial allegiance and support is generously provided by ACB, the Institute of Biomedical Science and the Royal College of Pathologists. labtestsonline.org.uk

Social media: Fostering community

The ACB invested in professional communications support and social media management tools to improve consistency and visibility of the ACB on social media. Social media channels were streamlined to make it easier for the membership and clinical scientists to get relevant information about the ACB's work. Engagement on Twitter has improved in 2019.

LOOKING FORWARD 2020/2021

- ◆ Launch new Members' database and website.
- ◆ Establish a committee devoted to commissioning best practice/guideline articles for *Annals*.
- ◆ Find relevant journals for the ACB's Immunologists and Microbiologists.
- ◆ Lab Tests Online-UK will work to increase annual traffic, ensure GPs have direct links to the website from their surgery, increase links with other public-facing websites and work with the ACB and Royal College of Pathologists to push for mandatory standards for systems that display test results directly to patients.

NATIONAL MEETINGS COMMITTEE

Organises the ACB's National Meetings on cutting-edge science to serve the membership and clinical medicine community.

Director: Sarah Robinson

FiLM and Focus 2019: Two successful conferences

In 2019, the two main ACB conferences: Frontiers in Laboratory Medicine and Focus were held. Both were successful and received positive feedback and made small profits.

FiLM was held in Birmingham in January and was a collaboration between the ACB and the Dark Report author Robert Michel, as in previous years. Focus was held in Glasgow in May and included two parallel streams: Focus on Service and Focus on Science. A Training Day was held before Focus and was well attended, covering topics on Sense about Science and Help! Do I need a Biochemist or an Immunologist? (see Education, Training and Workforce Committee report on page 6).

'A professional conference organiser has been contracted to help with FiLM and Focus for the next two years to support organisation, registration and promotion of these meetings'

FiLM and Focus 2020: Improved service, communication and programming

A fantastic programme has been put together to guarantee success. The process of abstract submission and review has been updated to ensure everything runs smoothly, which is easier for those submitting and reviewing.

A professional conference organiser, Conference Partners International, has been contracted to help with FiLM and Focus for the next two years to support organisation, registration and promotion of these meetings.

The 2020 meetings had support from a professional communications specialist on social media to help publicise and create a buzz about the meetings.

For FiLM 2020, additional members on the Committee supported the scientific programme activities. Sponsorship packages were redesigned to encourage enhanced participation from our colleagues in industry. A new Young Leaders Programme encouraged the pathology leaders of the future. Registered delegates had the opportunity to bring a Trainee to the conference at a heavily discounted price.



The Tall Ship, venue for the Focus 2019 conference dinner

LOOKING FORWARD 2020/2021

- ◆ Focus 2020 was due to be held in Belfast, the first time the meeting has been in Ireland; unfortunately due to the COVID-19 pandemic this meeting has been postponed, but will be held in Belfast in 2021.
- ◆ The ACB have the opportunity to submit a bid to host the EuroMedLab Congress in 2025. A number of regions have expressed an interest in hosting the conference so an internal selection process has been introduced to agree on the city most likely to be successful. An invitation has been sent to all regional chairs to submit a city in their region for consideration.
- ◆ During the early part of 2020 the meetings that are organised and held by the ACB will be reviewed to reflect the changing needs and challenges of the membership in order to ensure they are appropriate for the future workforce.

MICROBIOLOGY PROFESSIONAL COMMITTEE

Represents the interests of Microbiologists within the ACB and national professional bodies.

Chair: Dr Rob Shorten



Microbiologists' representation within the ACB

2019 saw a year of renewed vigour in our engagement with the ACB. The Committee acknowledged that we had not taken full advantage of our integration with the wider Association and therefore our members had not benefitted as much as we hoped when the Association for Clinical Microbiology dissolved and we joined ACB in 2010. As a small group of committed Clinical Scientists we aim to provide the best possible support to our members through representation within the ACB and beyond.

Training and education

The ACB Microbiology Committee is taking a leading role in reviewing the microbiology Scientific Training Programme curriculum to be finalised ahead of the 2021 intake. We continue to contribute to Clinical Scientist training via the National School of Healthcare Science. The Committee continues to improve the Objective Structured Final Assessment process ensuring final year Scientific Training Programme trainees receive high quality assessments when exiting the programme, therefore maintaining high standards within the profession.

Committee members continued to be involved in the Scientific Training Programme equivalence process and have undertaken assessments and provided training. Many members becoming Scientific Training Programme assessors are already ACS Distance Education assessors and this has

helped with the process. Likewise, Committee members are involved with assessing Higher Specialist Scientific equivalence via the Academy for Healthcare Science. There are a record number of microbiology posts being offered in 2020, but with potential changes in funding and Scientific Training Programme recruitment, it is expected that we will see an increase in the numbers of applicants via the equivalence route.

With workforce issues, demands on laboratories and a changing NHS landscape, having Committee members represent our professional body in key forums such as the Royal College of Pathologists is more important than ever for our members.

Clinical and scientific representation and contribution

The Committee has continued to provide representation to the ACB Scientific Committee including the ACB Scientific Scholarships. The committee also has formal representation at the PHE Standards for Microbiological Investigation Bacteriology and Virology Committees and has contributed to several guidance documents. We have also contributed to national guidance, for example the NICE guidance documents on Peezy urine collection devices and management of meningitis. Lastly, we are looking to collaborate with the National Infection Trainee Collaborative for Audit and Research on future clinical and scientific national audits.

Communication

In 2019 we continued to communicate with our members via the *ACB News* magazine and work closely with the ACB office on the website upgrade. This should act as an incredibly useful interface for current and prospective members. Finally, we have been more present on social media, sharing information on meetings, consultations and job opportunities at [@TheACBNews](https://twitter.com/TheACBNews) on Twitter using the hashtag [#ACBMicro](https://twitter.com/ACBMicro).

Annual meeting

After a break in 2018 we held an incredibly successful Annual Meeting in November 2019 at Tooley Street, showing a clear demand for such meetings covering scientific content and training updates.

LOOKING FORWARD

2020/2021

- ◆ Larger annual meeting and possibly holding two events per year.
- ◆ Increased contribution to Science Communication to ensure that information in the public domain relating to the laboratory diagnosis of infectious diseases is accurate.

IMMUNOLOGY PROFESSIONAL COMMITTEE

Represents the interests of Immunologists within the ACB and national professional bodies. The Immunology Professional Committee (IPC) represents the Immunology Professional Group (IPG) within the ACB.

Chair: Elizabeth Bateman



Education

This year has again been a successful year for Clinical Scientist training, with the number of Trainees going through the Scientific Training Programme scheme remaining stable and all Trainees successfully completing the training.

We continue to work with our medical colleagues and the Royal College of Pathologists regarding proposed changes to the Immunology FRCPath exams. This has been, and continues to be, a major focus of the Committee.

There continues to be a need to recruit more examiners for the FRCPath, and to progress changes to support the examination process.

In collaboration with the Education Committee, the ACB National Training Day at Focus 2019 was a joint day between immunology and biochemistry. Presentations on Interpretation of Immunoglobulins and Autoimmune Liver Disease were given by members of the IPG.

Workforce

The Committee has been gathering workforce data over the last year to get a picture of the number of immunology clinical scientists, locations, roles and projected retirement ages. The number of Immunology Clinical Scientists in training and the retention of those from the Scientific Training Programme has also been captured. The aim of this data collection is to help workforce planning and ensure sufficient training occurs to sustain the workforce.

Scientific

A separate national audit group for clinical immunology has been established with involvement from Clinical Scientists, medics and Biomedical Scientists. This is a group separate from any professional body, which IPG members actively participate in. The first survey on antineutrophil cytoplasmic antibodies testing has been completed and is being prepared for publication. The second survey on immunoglobulins and preliminary data analysis has been completed. The third audit is in the planning stage and will look at optimal interval testing time for a range of immunology tests.

‘A separate National Audit Group for Clinical Immunology has been established with involvement from Clinical Scientists, medics and Biomedical Scientists, including IPG members’

LOOKING FORWARD

2020/2021

- ◆ Establish a yearly immunology meeting with the aim to better support Scientific Training Programme trainees and clinical scientists in training.
- ◆ Update the immunology pages on the ACB website, including a map of UK centres that perform immunology testing and information on regional immunology services and training centres.

ACB AROUND THE UK AND IRELAND

The ACB Regional Committees serve local Clinical Scientists through scientific and training meetings, bursaries and awards. They are vital in keeping the ACB's membership thriving and regional Clinical Scientists supported through training and local Scientific Meetings.

1 NORTHERN IRELAND Chair: Dr Elinor Hanna

- ◆ 1 Scientific Meeting on diabetes and lipids, sponsored by Roche Diagnostics, NAPP and Amgen.
- ◆ 2 Regional Audit Group meetings.
- ◆ 2 regional newsletters circulated.
- ◆ 1 grant to attend ACB Microbiology Professional Group meeting awarded.
- ◆ Represented the ACB on Northern Ireland Pathology Network Board.
- ◆ Many ACB Members attended the Northern Ireland Pathology Network HSC Pathology Transformation Programme Stakeholder Engagement & Planning Workshop, which focused on procurement of a new Laboratory Information Management System, and standardisation of processes across the Trusts.

Dr Derek McKillop developed, and with other ACB Members launched, a Disease Detective pack for Cub Scouts, in partnership with the RCPATH and Northern Ireland Scout Association, to help Cub leaders deliver the health and science criteria of various badges and be a useful resource for schools and youth groups.

LOOKING FORWARD 2020/2021

- ◆ Progressing and future audits on add-on testing, national β -type natriuretic peptide audit, cerebrospinal fluid sampling quality and CSF lactate measurement, osmolality measurement, removal of results from contaminated samples, a clinical hyperkalaemia audit and current practice for minimum retest intervals.

2 REPUBLIC OF IRELAND Chair: Seán Costelloe (2019)/Jennifer Brady (2020)

- ◆ 1 Scientific Meeting on the topic of quality improvement.

LOOKING FORWARD 2020/2021

- ◆ 1 Scientific Meeting to include a Members' Papers section.
- ◆ An Audit Lead has been nominated and is planning audits with Regional Trainees.

3 WALES Chair: Dr Sharman Harris

- ◆ 2 Scientific Meetings on hepatology and gastroenterology.
- ◆ Free attendance to Autumn Scientific Meeting thanks to sponsorship.
- ◆ 1 Members' Papers Award awarded.
- ◆ 2 All Wales Clinical Biochemistry Audit Group meetings.
- ◆ Involved with National Pheochromocytoma Audit.
- ◆ 2 travel bursaries awarded for Trainees attending a mass spectrometry European Congress in Salzburg and a Wales Region Scientific Meeting.
- ◆ Weekly clinical biochemistry FRCPATH preparation tutorials for Trainees.

LOOKING FORWARD 2020/2021

- ◆ Spring Scientific Meeting on genetics and audit presentations.
- ◆ Ongoing audits on hypophosphatasia, 5HIAA/NET re-audit, fluids, hyperkalaemia.
- ◆ Carrying out audit plan for the next few years with Health Boards across Wales.
- ◆ 3 Scientist training programme posts in clinical biochemistry.

4 SOUTHERN Chair: Robyn Shea

- ◆ 1 Scientific Meeting on faecal markers and total parenteral nutrition.
- ◆ 3 Trainee meetings on biochemistry, with presentations on acid-base, liver, kidney and bone cases, duty biochemist cases, literature reviews and Scientific Training Programme elective presentations.
- ◆ 2 Thames Clinical Biochemistry Audit meetings on hirsutism/testosterone/adrenal androgens and externally referred tests.
- ◆ 2 Bill Richmond Prizes awarded.
- ◆ 2 bursaries awarded to attend the ACB Management Course.

LOOKING FORWARD 2020/2021

- ◆ 3 Scientific Meetings given the number of members in the region.



In 2019 regional committees held scientific events, gave out bursaries and awards and held vital training sessions locally. It was great to see the West Midlands Region Committee revived and planning activities for the coming years. Finding volunteers to take part in committees and organise events remains a challenge in some regions.



5	SCOTLAND Chair: Kevin Deans
	<ul style="list-style-type: none"> ◆ 1 Scientific Meeting on diabetes & endocrinology. ◆ 2 Audits (one ongoing).
	<p>LOOKING FORWARD 2020/2021</p> <ul style="list-style-type: none"> ◆ Spring and Autumn 2020 Scientific Meetings cancelled due to COVID-19. ◆ AGM postponed due to COVID-19 – when this is rescheduled, several committee members are due to demit, and new committee members will be elected. ◆ Audit Coordinator (Dr James Logie) exploring opportunities for further collaborative working between the Scotland Audit Group and the Scottish Clinical Biochemistry Network.
6	NORTH WEST Chair: Dr Shirley Bowles
	<ul style="list-style-type: none"> ◆ 2 Scientific Meetings, one with paediatric theme, all costs were covered by sponsorship from Biohit Healthcare Ltd and Alexion. ◆ 2 Ian Ward Members' Papers Meeting prizes awarded – first and runner up. ◆ Trust Audit Leads meetings. ◆ 1 ACB Scientific Scholarship awarded to member undertaking Higher Specialist Scientific Training to help support their doctoral project. <p>Monthly regional teaching sessions focused around Fellow of the Royal College of Pathologists preparation were well received in 2019, with attendees travelling from other deaneries where such a teaching programme does not exist.</p>
	<p>LOOKING FORWARD 2020/2021</p> <ul style="list-style-type: none"> ◆ 1 Regional Audit on procalcitonin, led by Ceri Rowe. ◆ 1 National Audit on faecal immunochemical testing, led by Natalie Hunt.
7	TRENT & NORTHERN YORKSHIRE Chair: Hannah Delaney
	<ul style="list-style-type: none"> ◆ 2 Scientific Meetings. ◆ 1 Regional Audit meeting. ◆ 3 regional newsletters sent. <p>High demand for regional exam preparation sessions for Trainees, such as tutorials, mock vivas and mock Objective Structured Practical Examinations (OSPE).</p>
	<p>LOOKING FORWARD 2020/2021</p> <ul style="list-style-type: none"> ◆ 3 Scientific Meetings. ◆ Explore ways Clinical Scientist and Medical Trainees across this large region prepare for exams together, e.g. a shared database of clinical cases and OSPE-type questions, remote tutorial sessions and communication via a regional WhatsApp group. ◆ Geoffrey Walker Award.
8	WEST MIDLANDS Chair: Pervaz Mohammed
	<ul style="list-style-type: none"> ◆ New Committee in place. ◆ Undertook a Trainee review to gain clarity on workforce and positions.
	<p>LOOKING FORWARD 2020/2021</p> <ul style="list-style-type: none"> ◆ Restart regional meetings after three years of pressures of network formations and consolidation has taken its toll on the Committee. ◆ Scientific Meeting with trace elements theme. ◆ Audit meeting in autumn 2020. ◆ Find Regional Audit Lead.
9	SOUTH WEST & WESSEX Chair: Anthea Patterson (2019)/Roanna George (2020)
	<ul style="list-style-type: none"> ◆ 1 Scientific Meeting on genetics. ◆ 1 Trainee study day on newborn screening – theory and management and analytical aspects of mass spectrometry. ◆ 1 Regional Audit on cryoglobulin.
	<p>LOOKING FORWARD 2020/2021</p> <ul style="list-style-type: none"> ◆ Scientific Meeting on immunology. ◆ Trainee study days based in regional hospitals. ◆ Encourage and disseminate audits.

FEDERATION OF CLINICAL SCIENTISTS

Certificated Trade Union, with full national recognition and negotiating rights, which represents the interests of Clinical Scientists in the NHS and other related areas. ACB Members can opt-in to become Federation of Clinical Scientists (FCS) Members.

Director of Regulatory Affairs and FCS Chair: Emma Lewis

Trade union discussions across the UK

This year the FCS have again been heavily involved with our wider trade union colleagues in all the countries of the union, and in discussions with a range of bodies to put forward our members' views. This has included joint responses to consultations with other unions and joint working on many aspects. We continue to feed into NHS Improvement, with the ongoing Pathology Improvement Project in England.

Salaries

While the pay situation in England, Wales and Scotland has been stable this year, Northern Ireland had not benefitted from the pay uplift in the last year. This has caused some serious tension within the health service in Northern Ireland but this now looks to be coming to a resolution, with a deal to increase pay in line with England.

Pensions

Several pension issues have been ongoing. The problems of the lifetime pension tax allowance hit this year and while this is mainly an issue for medical staff, it has affected some within the Federation. There was a fix this year introduced by the Treasury, which allowed those affected to mitigate their tax, but that is only for this financial year. The FCS, along with other unions, is pushing for a longer-term solution.

In December 2018, the Court of Appeal ruled that the 'transitional protection' offered to some members of the judges' and firefighters' schemes, as part of the reforms, gave rise to unlawful discrimination. While this judgement was originally on the judges and firefighter pension scheme, the government has stated it will apply to all public service pension schemes and is now working on how this should be rectified.

Casework and FCS representative training

Local and regional FCS representatives have been involved in casework this year, giving advice to members and supporting them when they are having difficulties. This has been a particularly busy year for genetics, with the formation of the genomic medicine hubs requiring extensive input from FCS representatives.

Several training sessions were organised for our regional and local representatives, with short interactive teleconference training proving to be great success. This allows representatives to participate in training on a particular topic without having to be away from their base.



LOOKING FORWARD 2020/2021

- ◆ Continue online training for FCS representatives as well as some in-person training days.
- ◆ Encourage members to fill gaps in the network of local and regional representatives.

EQUALITY, DIVERSITY & INCLUSION STATEMENT

This statement was adopted at the ACB's 2019 Annual General Meeting and guides the ACB's decision making process, particularly in terms of the awarding of prizes, funds and awards.

ACB Equality, Diversity and Inclusion Champion: Dr Rachel Wilmot



The Association for Clinical Biochemistry and Laboratory Medicine is an inclusive organisation, committed to eliminating discrimination and fostering a culture where individual differences and diversity are welcomed.

Our aim is that our Members and staff are representative of all sections of society and feel respected, engaged and able to give their best.

To that end we commit to, and comply with, the Equality Act 2010 and other relevant legislation: providing equality and fairness for all Members, employees and stakeholders, or those applying to be such; not discriminating on grounds of race, national origin, religion, belief, sex, sexual orientation, gender identity, disability, age, marriage or civil partnership, pregnancy, maternity or paternity. We oppose all forms of unlawful or unfair discrimination.

We recognise each person is an individual with visible and non-visible differences, celebrating and valuing these differences and by doing so ensuring we treat all Members and staff fairly, with respect and value all for their contributions.

We commit to proactively foster an environment where diversity is valued, barriers to participation eliminated and everyone feels they belong and are able to contribute to their fullest potential.

We recognise that inclusion goes beyond the consideration of legally protected characteristics and in an organisation representing clinical science we will welcome, respect and listen to our Members, and use the different perspectives and ideas that each brings to the ACB.

This statement will inform the way we discharge our responsibilities, perform our duties and make our decisions.

LOOKING FORWARD

2020/2021

- ◆ Continued inclusivity for all Members old and new.
- ◆ Re-benchmarking the ACB against other scientific and engineering organisations.

AWARDS, FUNDS AND PRIZES

The ACB awards, funds and prizes help support Members in their careers and recognise excellent work within the profession. The 2019 awardees and prize winners are congratulated here.

Educational travel grants

Five awarded to attend national and international conferences and training courses.

ACB Scientific Scholarships

Financial support awarded by the ACB Scientific Committee to up-and-coming scientists in the profession undertaking relevant research.

- ◆ Charlotte Armitage: *Association of progesterone and its neurosteroid metabolite, allopregna-nolone, with inflammation in patients with perinatal depression.*
- ◆ Julie Tarling: *Prognostic value of kisspeptin as a biomarker to distinguish between miscarriage and viable pregnancies.*
- ◆ Karen Perkins: *Development of a tandem mass spectrometry method for biotin measurement to investigate biotin interference in immunoassays for biomarkers of placental dysfunction.*
- ◆ Caroline Hyam: *Prevalence of macrotroponin in patients with elevated cardiac troponin I using the Siemens Advia Centaur® high sensitivity method.*
- ◆ Christopher McClean: *Investigating the co-abuse of antidepressants by patients monitored by drugs of abuse using tandem mass spectrometry.*
- ◆ Joseph Taylor: *Assessing pre-analytical factors and optimisation of analytical conditions to facilitate study of the metabolome associated with adrenal incidentaloma using high-resolution accurate-mass mass spectrometry.*



The 2019 Clinical Case presenters with Dr Danielle Freedman and Dr Kevin Deans at Focus 2019 in Glasgow

ACB Foundation Award

Award for plenary lecture at Focus:

- ◆ Dr Joanna Sheldon

ACB/AACC Transatlantic Award Lecture

Award for Transatlantic Plenary Lecture at Focus:

- ◆ Dr Carmen Wiley, Minnesota

ACB Medal Award

This award is made on the basis of an oral communication presented by a Member of the Association at Focus.

The winner receives a silver medal and both the winner and runner-up receive a bursary. The bursaries are intended to help enable attendance at a Scientific Meeting, or to fund research work.

- ◆ Winner: Dr David Church
- ◆ Runner up: David Marshall

ACB Poster Prizes

Two prizes awarded at Focus for the best poster describing a clinical case(s) and the best poster describing a clinical audit.

Prizes are intended to enable attendance at a Scientific Meeting, or to fund research work.

- ◆ Clinical cases: Dr Andreas Tridimas
- ◆ Audit: Katherine Wright

ACB Oral Presentation Award

Prize awarded at Focus for the best oral clinical case presentation, as voted for by the audience.

- ◆ Winner: Jennifer Nobes
- ◆ Runner up: Laura Briggs

President's Shield

Awarded by the current President of the ACB to mark an outstanding contribution to the Association:

- ◆ Dr Rachel Wilmot for development of the ACB Equality, Diversity and Inclusion Strategy.

Don Henderson Award

Presented annually at the Schools Science Conference, an event that ACB Member Don Henderson helped establish and one of the ways the ACB promotes itself to the wider community. The conference explains the work done in healthcare sciences and laboratory medicine and encourages young people to take an interest in science and careers in the health services. The school that submits the best report and presentation on a piece of research they have undertaken gets an annual award of book tokens and presentation of a shield.

- ◆ Fulham Boys School

Membership Award

Members that have made a distinguished contribution to the development of either the Association or the profession in general can be awarded one of three honorary titles: Honorary, Emeritus or Fellow.

Nominated by	Nominee	Award
Wales Region	Dr David Cassidy	Emeritus
Scotland Region	Dr Bill Bartlett	Honorary
Southern Region	Mrs Zahra Khatami	Honorary
Southern Region	Prof Jonathan Kay	Honorary
Trent, Northern & Yorkshire Region & North West Region	Mr Gilbert Wieringa	Honorary
Trent, Northern & Yorkshire Region	Dr Julian Barth	Honorary
Southern Region	Mr Barry Sampson	Fellow
Southern Region	Dr Laila Tibi	Fellow
Southern Region	Dr Gill Rumsby	Fellow
Southern Region	Dr Kerry Whiting	Fellow
South West & Wessex Region	Dr Angela Mallard	Fellow
North West Region	Mr Tony Tetlow	Fellow
Trent, Northern & Yorkshire Region	Mr Ian Hanning	Fellow
Trent, Northern & Yorkshire Region	Dr Jean Wardell	Fellow

The ACB holds two Trusts from which Members can draw:

ACB Benevolent Fund

Established to aid persons who are or have been Members or employees of the Association, whether they are subscribers to the fund or not, and the dependents of past or present Members or employees of the ACB who have died or are experiencing difficulties with some abilities. In 2019, the ACB made an award from the fund to one Member.

CP Stewart Memorial Fund

Established by the former Chair and President of the Association. It is intended to fund the advancement of scientific knowledge and education by providing financial support to enable scientists to visit laboratories within the United Kingdom or elsewhere, for the purposes of learning specialised techniques or to obtain first-hand knowledge from a recognised expert in a field that will assist them in their studies. In 2019, £300 was awarded to ACB Members.

Regional awards, funds and prizes

North West

Ian Ward Members' Papers Presentation Prize

- ◆ First prize: Andreas Tridimas: *A challenging case of hypercalcaemia in a 33-year old male.*
- ◆ Runner-up: Niamh Horton: *Alpha-1 anti-trypsin deficiency: a case of the incidental and yet forgotten deficiency.*

Northern Ireland

- ◆ Bursary to attend the ACB Microbiology Professional Group Annual Microbiology Scientific & Training Meeting was awarded to Ciara Cox.

Scotland

John King Award

- ◆ Dr Louisa Lee for her presentation on Development and validation of an LC-MSMS method for the measurement of DHEAS.

Southern

Bursary to assist with attending the ACB Management Course:

- ◆ Naomi Elkin
- ◆ Jenny Lake

Bill Richmond Prize

- ◆ Felicity Stokes: *An unusual cause of abdominal pain.*
- ◆ Thomas Morris: *Prognostic role of the eGFR. in differentiating between true and pseudohyperkalaemia.*

Wales

Members' Papers Award

- ◆ Dr Anthony Jackson-Crawford: *CSF Kappa free light chains in the diagnosis of MS.*

Lifetime Achievement Award from the Welsh government's first ever UK Allied Health Professionals Awards Ceremony

- ◆ Annette Thomas for her tremendous contribution to clinical science, quality assurance and point of care testing throughout her career.


Travel bursaries

The Wales Regional Committee also awarded two travel bursaries:

- ◆ Bursary for travel to Mass Spectrometry European Congress in Salzburg.
- ◆ Bursary for travel to the Wales Region Scientific Meeting.

DIRECTOR OF FINANCE'S REPORT

Dr Mike Bosomworth, Director of Finance



'... within every challenge lies opportunity and we can only take advantage of those opportunities ...'

Firstly I would like to thank our staff for their continued hard work and commitment to our Association. In addition, I would also like to thank my fellow members of ACB Council and Executive, our regional committees and officers and our regional and National Meetings organisers for their immense contribution to our Association.

Turning to our financial position performance during 2019, we had a significant loss of £53,241. This is largely a consequence of our office review, the appointment of an interim Chief Executive and our need for expert human resources advice, especially during the appointment of substantive Chief Executive Jane Pritchard. We are projecting a loss of approximately £120,000 this year as we replace aging IT software and management systems. These are very necessary changes if the ACB is to prosper in what is an increasingly challenging environment. However, within every challenge lies opportunity and we can only take advantage of those opportunities if we have an efficient and responsive management function.

Speaking of challenges, the current Coronavirus pandemic will undoubtedly impact on the ACB's operations, our suppliers, Members, employees and our investments. However, it is still appropriate to

prepare the financial statements on a going concern basis, despite the anticipated fall in market value of our investments (approximately 20%). The good news is that our investments will almost certainly recover over time and that we have no imminent need to draw down from them.

Our auditors Buzzacott LLP have issued an unqualified report on the ACB's accounts.

The ACB is responsible for three charities:

1. **Clinical Biochemistry Conferences**, the funds of which are available to support educational activities and scientific scholarships. In 2019 awards were made totalling £9,141.
2. **The CP Stewart Memorial Fund** that is available to support Members wishing to learn new techniques with a view to using them in their own laboratories. £300 was awarded in 2019.
3. **The Benevolent Fund** that supports Members and the Association's staff in times of need. £5,756 was awarded in 2019.

Financial statements and independent examinations of our Trusts (Clinical Biochemistry Conferences, CP Stewart and The Benevolent Fund) are all completed and approved by the relevant Trustees.

ACCOUNTS – REPORT & FINANCIAL STATEMENTS

For the year ended 31 December 2019

Directors	Dr N R Anderson Ms C F Baillie Mrs S C Benton (resigned 14 May 2019) Mrs H A Borthwick Dr M P Bosomworth Dr S A Bowles Dr C Chaloner (resigned 3 May 2019) Dr S J Costelloe Dr K A Deans Dr C J Duff Prof J Geen (resigned 26 November 2019) Dr E Hanna Dr S Holding (resigned 3 May 2019) Mrs N Jassam (resigned 3 May 2019) Miss K Kaur Dr E J Lewis Mr P Newland (resigned 7 November 2019) Dr M J O’Kane (resigned 3 May 2019) Dr A L Patterson Dr R L Webster (resigned 3 May 2019) Dr B L Croal (appointed 3 May 2019) Dr H Delaney (appointed 3 May 2019) Dr S J Glover (appointed 3 May 2019) Dr S D Harris (appointed 3 May 2019) Mr P Mohammed (appointed 3 May 2019) Dr M V Patel (appointed 3 May 2019) Dr R Shea (appointed 3 May 2019) Mrs A M Yates (appointed 3 May 2019) Prof I S Young
Company secretary	Dr S J Glover
Registered number	00863235
Registered office	130-132 Tooley Street London SE1 2TU
Independent auditor	Buzzacott LLP 130 Wood Street London EC2V 6DL

Directors’ Report

The directors present their report and the financial statements for the year ended 31 December 2019.

Directors’ responsibilities statement

The directors are responsible for preparing the Directors’ report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the Company’s financial statements and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company’s transactions and disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Directors

The directors who served during the year were as listed above.

Future developments

The Association's overall objectives remain unchanged. They include activities relating to education and training (including the organisation of regional and National Meetings), the promotion of research and development, publishing, public engagement and cooperation with nationally and internationally based cognate organisations. We do not expect these objectives to change materially in the next 12 months.

The worldwide outbreak of the coronavirus pandemic (COVID-19) has caused extensive disruptions to organisations globally with major implications for both its operations and finances. The directors acknowledge and recognise the potential impact of the COVID-19 pandemic on the future operations of the Association, its Members, partners, stakeholders and on the wider society. Key areas of the company's operations that have been impacted include:

- Following the advice issued by the UK Government in March 2020 regarding employees working from home and other social distancing measures, staff are not permitted to work at the Company's offices, however we have enacted procedures to facilitate remote working and have taken detailed action that enables effective operation of the company to continue, whilst employees are not physically present in the office.
- Association's meetings and events – The Association will not be able to convene events such as its Focus 2020 meeting as well as other smaller scientific based meetings and events, however in both cases these meetings can be re-convened at a later date with the Focus meeting deferred to 2021. Where practicable we are using online technology to host smaller meetings on a virtual basis.

The directors are satisfied with the alternative plans that have been put in place to ensure that disruption to the Association's operations arising from COVID-19 is minimised. The deferral of the Focus meeting until 2021 does not have a detrimental affect on the Association's finances, as the Association has diversified income streams that have remained robust.

The directors are therefore of the opinion that despite the impact of COVID-19, the Association remains a going concern over the next twelve months from the signing of the financial statements.

Disclosure of information to auditor

Each of the persons who are directors at the time when this Directors' report is approved has confirmed that:

- so far as the director is aware, there is no relevant audit information of which the Company's auditor is unaware, and
- the director has taken all the steps that ought to have been taken as a director in order to be aware of any relevant audit information and to establish that the Company's auditor is aware of that information.

Small companies note

In preparing this report, the directors have taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006.

This report was approved by the board on and signed on its behalf by

Dr M P Bosomworth, Director
29 May 2020

Independent Auditor's Report to the Members of The Association for Clinical Biochemistry and Laboratory Medicine

Opinion

We have audited the financial statements of The Association for Clinical Biochemistry and Laboratory Medicine (the 'Company') for the year ended 31 December 2019, which comprise the Statement of comprehensive income, the Statement of financial position, the Statement of changes in equity and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the Company's affairs as at 31 December 2019 and of its loss for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs [UK]) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the directors' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the directors have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the Company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Other information

The directors are responsible for the other information. The other information comprises the information included in the Directors' Report and the Director of Finance's Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Directors' report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Directors' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the Directors' report and from the requirement to prepare a Strategic report.

Responsibilities of directors

As explained more fully in the Directors' responsibilities statement on page 19, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditor's report.

Use of our report

This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an Auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members, as a body, for our audit work, for this report, or for the opinions we have formed.

*Mark Worsley (Senior statutory auditor)
for and on behalf of Buzzacott LLP, London
29 May 2020*

Statement of comprehensive income

For the year ended 31 December 2019

	Note	2019 £	2018 £
Turnover		733,474	790,943
Cost of sales		<u>-</u>	<u>(14,068)</u>
Gross profit		733,474	776,875
Administrative expenses		(883,205)	(703,658)
Unrealised gain/(loss) on listed investments	4	<u>75,322</u>	<u>(82,175)</u>
Operating loss		(74,409)	(8,958)
Income from fixed assets investments		18,790	19,109
Amounts written off investments		15,149	17,252
Interest receivable and similar income		<u>1,244</u>	<u>584</u>
(Loss)/profit before tax		(39,226)	27,987
Tax on (loss)/profit		<u>(14,015)</u>	<u>12,475</u>
(Loss)/profit for the financial year		<u>(53,241)</u>	<u>40,462</u>
Other comprehensive income for the year			
Total comprehensive income for the year		<u>(53,241)</u>	<u>40,462</u>

There were no recognised gains and losses for 2019 or 2018 other than those included in the statement of comprehensive income.

The notes on pages 23 to 28 form part of these financial statements.

Statement of financial position

As at 31 December 2019

	Note	2019 £	2018 £
Fixed assets			
Tangible assets	10	677,635	687,443
Investments	11	<u>1,606,991</u>	<u>1,525,651</u>
		2,284,626	2,213,094
Current assets			
Debtors	12	143,047	125,758
Cash at bank and in hand		<u>443,408</u>	<u>546,034</u>
		586,455	671,792
Creditors: amounts falling due within one year	13	<u>(343,201)</u>	<u>(316,570)</u>
Net current assets		<u>243,254</u>	<u>355,222</u>
Total assets less current liabilities		2,527,880	2,568,316
Provisions for liabilities			
Deferred tax	14	<u>(68,339)</u>	<u>(55,534)</u>
		<u>(68,339)</u>	<u>(55,534)</u>
Net assets		<u>2,459,541</u>	<u>2,512,782</u>
Capital and reserves			
Revaluation reserve	15	401,995	326,673
Other reserves	15	1,813,737	1,802,949
Profit and loss account	15	<u>243,809</u>	<u>383,160</u>
		<u>2,459,541</u>	<u>2,512,782</u>

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on

Dr M P Bosomworth, Director
29 May 2020

The notes on pages 23 to 28 form part of these financial statements.

Statement of changes in equity

For the year ended 31 December 2019

	Revaluation reserve £	Other reserves £	Profit and loss account £	Total equity £
At 1 January 2019	326,673	1,802,949	383,160	2,512,782
Comprehensive income for the year				
Loss for the year	—	—	(53,241)	(53,241)
Total comprehensive income for the year	—	—	(53,241)	(53,241)
Transfer to/from profit and loss account	<u>75,322</u>	<u>10,788</u>	<u>(86,110)</u>	—
At 31 December 2019	<u>401,995</u>	<u>1,813,737</u>	<u>243,809</u>	<u>2,459,541</u>

The notes on pages 23 to 28 form part of these financial statements.

Statement of changes in equity

For the year ended 31 December 2018

	Revaluation reserve £	Other reserves £	Profit and loss account £	Total equity £
At 1 January 2018	408,848	1,832,490	230,982	2,472,320
Comprehensive income for the year				
Profit for the year	—	—	40,462	40,462
Total comprehensive income for the year	—	—	40,462	40,462
Transfer to/from profit and loss account	<u>(82,175)</u>	<u>(29,541)</u>	<u>111,716</u>	—
At 31 December 2018	<u>326,673</u>	<u>1,802,949</u>	<u>383,160</u>	<u>2,512,782</u>

The notes on pages 23 to 28 form part of these financial statements.

Notes to the Financial Statements

1. General information

The company is a private company limited by guarantee and is incorporated in the United Kingdom (England and Wales). Its registered office and principal place of business is 130-132 Tooley Street, London, SE1 2TU. The company registration number is 00863235.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.

The company is a parent undertaking of a small group and as such is not required by Companies Act 2006 to prepare group accounts. These financial statements therefore present information about the company as an individual undertaking and not about its group.

The following principal accounting policies have been applied:

2.2 Going concern

The company's forecasts and projections, taking account of reasonably possible changes in trading performance, show that the company can meet its liabilities as they fall due. In making this decision, the directors have taken into consideration the risks and uncertainties arising from the COVID-19 pandemic.

On this basis, the directors consider that the company will continue in operational existence for the foreseeable future and accordingly the directors consider it appropriate to prepare the financial statements on a going concern basis.

2.3 Turnover

Turnover comprises revenue recognised by the company in respect of goods and services supplied during the year, exclusive of Value Added Tax and trade discounts.

Annual subscriptions are allocated according to their renewal date which runs synchronous with the financial year. Subscriptions relating to the year under review are included in the Statement of comprehensive income and those relating to the following year are shown in creditors as deferred income.

Rendering of services

Turnover from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:

- the amount of turnover can be measured reliably;
- it is probable that the Company will receive the consideration due under the contract;
- the stage of completion of the contract at the end of the reporting period can be measured reliably; and
- the costs incurred and the costs to complete the contract can be measured reliably.

2.4 Operating leases: the Company as lessee

Rentals paid under operating leases are charged to the Statement of comprehensive income on a straight line basis over the lease term.

2.5 Interest income

Interest income is recognised in the Statement of comprehensive income using the effective interest method.

2.6 Pensions

Group personal pension plan

The Company operates a defined contribution group personal pension scheme for its employees. Annual contributions by the company in respect of the group personal pension scheme available to staff members are charged to the Statement of Comprehensive income in the period in which they are payable.

2.7 Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in the Statement of comprehensive income, except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the Statement of financial position date, except that:

- The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
- Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

2.8 Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

The estimated useful lives range as follows:

Software	-	3 years
----------	---	---------

2.9 Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

The Company adds to the carrying amount of an item of fixed assets the cost of replacing part of such an item when that cost is incurred, if the replacement part is expected to provide incremental future benefits to the Company. The carrying amount of the replaced part is derecognised. Repairs and maintenance are charged to profit or loss during the period in which they are incurred.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Long-term leasehold property	-	2%
Office equipment	-	25%
Computer equipment	-	33%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in the Statement of comprehensive income.

2.10 Valuation of investments

Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in the Statement of comprehensive income for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

Investments in listed company shares are remeasured to market value at each Statement of financial position date. Gains and losses on remeasurement are recognised in profit or loss for the period.

2.11 Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

2.12 Creditors

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

2.13 Provisions for liabilities

Provisions are made where an event has taken place that gives the Company a legal or constructive obligation that probably requires settlement by a transfer of economic benefit, and a reliable estimate can be made of the amount of the obligation.

Provisions are charged as an expense to the Statement of comprehensive income in the year that the Company becomes aware of the obligation, and are measured at the best estimate at the Statement of financial position date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties.

When payments are eventually made, they are charged to the provision carried in the Statement of financial position.

2.14 Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of comprehensive income.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate of the recoverable amount, which is an approximation of the amount that the Company would receive for the asset if it were to be sold at the reporting date.

3. Turnover

The whole of the turnover is attributable to promoting the advancement of Clinical Biochemistry and Laboratory Medicine. All turnover arose within the United Kingdom.

4. Unrealised gain/(loss) on listed investments

	2019	2018
	£	£
Unrealised gain/(loss) on listed investments	75,322	(82,175)
	<u>75,322</u>	<u>(82,175)</u>

5. Operating loss

The operating loss is stated after charging:

	2019	2018
	£	£
Depreciation of tangible fixed assets	25,432	31,601
Amortisation of intangible fixed assets, including goodwill	-	680
Fees payable to the company's auditor for the audit of the company's financial statements	14,000	12,000
Defined contribution pension cost	14,120	13,932
	<u>14,000</u>	<u>13,932</u>

6. Employees

The average monthly number of employees, including directors, during the year was 6 (2018 -6).

7. Interest receivable

	2019	2018
	£	£
Income from fixed asset investments	1,244	584
	<u>1,244</u>	<u>584</u>

8. Taxation

	2019 £	2018 £
Corporation tax		
Current tax on profits for the year	491	1,128
Adjustments in respect of previous periods	<u>719</u>	<u>3,790</u>
	<u>1,210</u>	<u>4,918</u>
Total current tax	<u>1,210</u>	<u>4,918</u>
Deferred tax		
Origination and reversal of timing differences	<u>12,805</u>	<u>(17,393)</u>
Total deferred tax	12,805	(17,393)
Taxation on profit/(loss) on ordinary activities	<u>14,015</u>	<u>(12,475)</u>

Factors affecting tax charge for the year

The tax assessed for the year is higher than (2018 - higher than) the standard rate of corporation tax in the UK of 19% (2018 - 19%). The differences are explained below:

	2019 £	2018 £
(Loss)/profit on ordinary activities before tax	<u>(39,226)</u>	<u>27,987</u>
(Loss)/profit on ordinary activities multiplied by standard rate of corporation tax in the UK of 19% (2018 - 19%)	(7,453)	5,318
Effects of:		
Adjustments to tax charge in respect of prior periods	719	3,790
Other timing differences leading to an increase (decrease) in taxation	20,749	(21,583)
Total tax charge for the year	<u>14,015</u>	<u>(12,475)</u>

9. Intangible assets

	Software £
Cost	
At 1 January 2019	<u>2,040</u>
At 31 December 2019	<u>2,040</u>
Amortisation	
At 1 January 2019	<u>2,040</u>
At 31 December 2019	<u>2,040</u>
Net book value	
At 31 December 2019	<u>-</u>
At 31 December 2018	<u>-</u>

10. Tangible fixed assets

	Long-term leasehold property £	Office equipment £	Computer equipment £	Total £
Cost or valuation				
At 1 January 2019	1,068,067	58,199	36,010	1,162,276
Additions	<u>-</u>	<u>-</u>	<u>15,624</u>	<u>15,624</u>
At 31 December 2019	<u>1,068,067</u>	<u>58,199</u>	<u>51,634</u>	<u>1,177,900</u>
Depreciation				
At 1 January 2019	384,281	57,647	32,905	474,833
Charge for the year on owned assets	<u>21,361</u>	<u>552</u>	<u>3,519</u>	<u>25,432</u>
At 31 December 2019	<u>405,642</u>	<u>58,199</u>	<u>36,424</u>	<u>500,265</u>
Net book value				
At 31 December 2019	<u>662,425</u>	<u>-</u>	<u>15,210</u>	<u>677,635</u>
At 31 December 2018	<u>683,786</u>	<u>552</u>	<u>3,105</u>	<u>687,443</u>

11. Fixed asset investments

	Listed investments £	Unlisted investments £	Total £
Cost or valuation			
At 1 January 2019	1,425,651	100,000	1,525,651
Additions	212,815	-	212,815
Disposals	(222,147)	-	(222,147)
Revaluations	<u>90,672</u>	<u>-</u>	<u>90,672</u>
At 31 December 2019	<u>1,506,991</u>	<u>100,000</u>	<u>1,606,991</u>
Net book value			
At 31 December 2019	<u>1,506,991</u>	<u>100,000</u>	<u>1,606,991</u>
At 31 December 2018	<u>1,425,651</u>	<u>100,000</u>	<u>1,525,651</u>

The cost of listed investments (including cash held awaiting investment) at 31 December 2019 was £1,086,677 (2018 - £1,080,659). Unlisted investments are comprised of £100,000 Lombard International Bond. Accordingly they are included at cost less provision for any permanent diminution in value.

The Association for Clinical Biochemistry and Laboratory Medicine is the parent undertaking of Clinical Biochemistry Conferences. Clinical Biochemistry Conferences is a company limited by guarantee and a registered charity. The company was incorporated on 8 January 2003 and the objects of the charity are to advance, spread and increase the knowledge, for the public benefit, of all aspects of the study of medical science concerned with clinical biochemistry and laboratory medicine and their diagnostic systems.

Clinical Biochemistry Conferences prepares accounts to 31 December. The latest accounts prepared for the year ended 31 December 2019 showed a loss of £9,962 (2018 - £11,289) and total reserves of £66,358 (2018 - £76,320).

12. Debtors

	2019 £	2018 £
Trade debtors	94,743	87,262
Other debtors	3,158	9,497
Prepayments and accrued income	<u>45,146</u>	<u>28,999</u>
	<u>143,047</u>	<u>125,758</u>

13. Creditors: Amounts falling due within one year

	2019 £	2018 £
Trade creditors	140,375	68,476
Amounts owed to group undertakings	66,595	75,989
Corporation tax	491	1,199
Other taxation and social security	9,285	15,308
Other creditors	92,578	94,023
Accruals and deferred income	<u>33,877</u>	<u>61,575</u>
	<u>343,201</u>	<u>316,570</u>

14. Deferred taxation

	2019 £	2018 £
At beginning of year	(55,534)	(72,927)
Charged to profit or loss	<u>(12,805)</u>	<u>17,393</u>
At end of year	<u>(68,339)</u>	<u>(55,534)</u>

The provision for deferred taxation is made up as follows:

	2019 £	2018 £
Provision for timing differences	<u>(68,339)</u>	<u>(55,534)</u>

15. Reserves

Revaluation reserve

The revaluation reserve represents the unrealised increase in market value above original cost on listed investments held at the end of the financial period.

Other reserves

The fixed asset fund represents the balance of the Association's funds that are invested in tangible fixed assets, intangibles and investments at cost less depreciation, amortisation provision for any diminution in value and also less the balance owed to the Clinical Biochemistry Conferences.

Profit and loss account

Includes all other current and prior period retained profits and losses.

16. Company status

The company is a private company limited by guarantee and consequently does not have share capital. Each of the members is liable to contribute an amount not exceeding £1 towards the assets of the company in the event of liquidation.

17. Pensions

The company operates a defined contribution pension scheme on behalf of its employees. During the year, pension contributions for those staff amounted to £14,120 (2018 - £13,932). At the 31 December 2019 the amounts payable with respect to amounts owed to the pension scheme amounted to £1,398 (2018 - £1,779).

18. Commitments under operating leases

At 31 December 2019 the Company had future minimum lease payments under non-cancellable operating leases as follows:

	2019	2018
	£	£
Later than 5 years	<u>583,500</u>	<u>583,800</u>
	<u>583,500</u>	<u>583,800</u>

19. Related party transactions

During the year the company repaid £9,394 of the loan due to the Clinical Biochemistry Conferences. At 31 December 2019 £66,595 (2018 - £75,989) was due to the Clinical Biochemistry Conferences, a subsidiary of the Association, in the form of an interest-free loan.

During the year the company received amounts totalling £5,232 (2018 - Nil) from the CP Stewart Memorial Fund. At 31 December 2019 £Nil (2018 - £5,232) was due from CP Stewart Memorial Fund, a charity of which Mr M P Bosomworth, Dr N R Anderson and Mr P Newland are Trustees.

20. Post balance sheet events

Since the year-end the value of the Association's investments has markedly decreased as a result of the economic implications of the COVID-19 pandemic. The loss on investments is consistent with all organisations that currently hold investments given that financial markets have decreased globally. The Association plans to hold its investments over the long-term and therefore all unrealised losses on investments arising from the economic impact of COVID-19 will be temporary and over the long-term the valuation of its investments will reflect robust fundamentals. On this basis the directors are of the opinion that no adjustments are necessary within these financial statements.

BENEVOLENT FUND

For the year ended 31 December 2019

Trustees	Dr M P Bosomworth, Treasurer and Secretary Dr J Horner Mrs R Lapworth MBE Dr W J Marshall Dr H Worth Prof N R Anderson, President and Chair
Charity Number	254213
Principal Address	c/o The Association for Clinical Biochemistry and Laboratory Medicine 130-132 Tooley Street London SE1 2TU
Independent Examiner	Buzzacott LLP 130 Wood Street London EC2V 6DL
Bankers	HSBC Bank Plc 281 Chiswick High Street Chiswick London W4 4HJ

Trustees' report

The Trustees present their annual report together with the financial statements of The Association of Clinical Biochemists Benevolent Fund ('the charity') for the year ended 31 December 2019.

The report has been prepared in accordance with Part 8 of the Charities Act 2011.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 of the attached financial statements and comply with the Charity's Deed of Trust, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice (SORP) applicable to charities preparing their financial statements in accordance with 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' ('FRS 102') effective for accounting periods commencing 1 January 2015 or later.

Structure, governance and management

Constitution

The charity is governed by a Deed of Trust dated 24 October 1967 as amended by Deed and Resolution dated 15 May 2013.

Method of appointment or election of Trustees

The management of the charity is the responsibility of the Trustees who are elected and co-opted under the terms of the Deed of Trust. The Trustees meet on an ad-hoc basis to consider issues. Day to day decisions in relation to the organisation and management of the Charity are contracted to a third party.

New Trustees are appointed by the Trustees with reference to the needs of the business and the particular attributes of the individuals under consideration. Induction and training of new Trustees is conducted by the Secretary.

The trustees who served during the year were:

Dr M P Bosomworth, Treasurer and Secretary
Dr J Horner
Mrs R Lapworth MBE
Dr W J Marshall
Dr H Worth
Prof N R Anderson, President and Chair (appointed 28 May 2019)
Prof I S Young, President and Chair (resigned 28 May 2019)

Key management personnel remuneration

The Trustees consider the board of Trustees as comprising the key management personnel of the charity in charge of directing and controlling the Charity and running and operating the charity on a day to day basis. All Trustees give their time freely and there was no Trustee remuneration or expenses paid in the year.

Policies and objectives

The objective of the charity is the help of necessitous persons who are, or have been, members or employees of the charity, whether they are subscribers to the Fund or not and of the dependants of deceased or disabled past or present members or employees of the Association.

Achievements and performance

Going Concern

After making appropriate enquiries, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future.

The worldwide outbreak of the coronavirus pandemic (COVID-19) has caused extensive disruptions to organisations globally with major implications for operations as well as finances. The Trustees acknowledge and recognise the potential impact of the COVID-19, however given that the charity has no staff, and whose sole purpose is to award grants which are subject to available reserves, the Trustees continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the accounting policies.

Review of activities

The net expenditure for the year was £5,230 (2018 - £5,324).

Financial review

Principal risks and uncertainties

The Trustees have reviewed all major risks to which the Charity is exposed and established systems to mitigate them. The Trustees have been aware of the Charity's dependence on the Trustees' own time and energies, voluntarily donated.

Reserves Policy

It is the policy of the charity to maintain unrestricted funds which are adequate to fulfil the objectives of the charity, subject to the limitations placed on the use of funds which has resulted in reserves building up to the current level. Any surplus funds are held in investments or short term deposits to help maintain the income levels for future years. Amounts have been paid to beneficiaries over the past few years and the Trustees will endeavour to find suitable persons whom the charity can help.

At 31 December 2019, reserves amounted to £27,334 (2018 - £32,564). The Trustees consider the current level of reserves to be sufficient to meet the future objectives of the Charity.

Public benefit

The Trustees have given due consideration to the Charity Commission published guidance on the public benefit requirements. The Trust constitutes a public benefit entity as defined by FRS 102.

Plans for the future

Future developments

There are no plans to change the strategies employed to carry out the objectives of the charity.

Trustees' responsibilities statement

The Trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with Financial Reporting Standard applicable in the UK and Republic of Ireland ('FRS 102');
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the applicable Charity (Accounts and Reports) Regulation and the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the Charity and financial information included on the Charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

This report was approved by the Trustees and signed on its behalf by:

Dr M P Bosomworth, Trustee
29 May 2020

Independent examiner's report

I report to the charity's Trustees on the accounts of the charity for the year ended 31 December 2019, which are set out on pages 31-33.

This report is made solely to the charity's Trustees, as a body, in accordance with section 145 of the Charities Act 2011 and regulations made under section 154 of the Charities Act 2011. My work has been undertaken so that I might state to the charity's Trustees those matters I am required to state to them in an independent examiner's report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the charity and the charity's Trustees, as a body, for my work or this report.

Respective responsibilities of Trustees and examiner

As the Trustees of the charity you are responsible for the preparation of the accounts, in accordance with the terms of the Charities Act 2011 ('the Act').

I report in respect of my examination of the charity's accounts as carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable directions given by the Charity Commission under 145 (5) (b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm no matter has come to my attention giving me cause to believe that in any material respect:

- accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
- the accounts do not accord with those records; or
- the accounts do not comply with the accounting requirements concerning the form and content of the accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

*Mark Worsley FCA
for and on behalf of Buzzacott LLP, London
29 May 2020*

Statement of financial activities (incorporating an income and expenditure account)

For the year ended 31 December 2019

	Note	Unrestricted Funds 2019 £	Total Funds 2019 £	Total Funds 2018 £
Income				
Donations		<u>400</u>	<u>400</u>	<u>567</u>
Total income		<u>400</u>	<u>400</u>	<u>567</u>
Expenditure				
Charitable activities		<u>5,630</u>	<u>5,630</u>	<u>5,891</u>
Total expenditure	2	<u>5,630</u>	<u>5,630</u>	<u>5,891</u>
Net expenditure		(5,230)	(5,230)	(5,324)
Net movement in funds		(5,230)	(5,230)	(5,324)
Reconciliation of funds				
Total funds brought forward		<u>32,564</u>	<u>32,564</u>	<u>37,888</u>
Total funds carried forward		<u>27,334</u>	<u>27,334</u>	<u>32,564</u>

All gains and losses arising in the year have been included in the Statement of Financial Activities and arise from continuing operations.

The notes on pages 32 to 33 form part of these financial statements.

Statement of financial activities (incorporating an income and expenditure account)

For the year ended 31 December 2018

	Note	Unrestricted Funds 2018 £	Total Funds 2018 £	Total Funds 2017 £
Income				
Donations		<u>567</u>	<u>567</u>	<u>1,092</u>
Total income		<u>567</u>	<u>567</u>	<u>1,092</u>
Expenditure				
Charitable activities		<u>5,891</u>	<u>5,891</u>	<u>6,355</u>
Total expenditure	2	<u>5,891</u>	<u>5,891</u>	<u>1,145</u>
Net expenditure		(5,324)	(5,324)	(5,263)
Net movement in funds		(5,324)	(5,324)	(5,263)
Reconciliation of funds				
Total funds brought forward		<u>37,888</u>	<u>37,888</u>	<u>43,151</u>
Total funds carried forward	5	<u>32,564</u>	<u>32,564</u>	<u>37,888</u>

All gains and losses arising in the year have been included in the Statement of Financial Activities and arise from continuing operations.

The notes on pages 32 to 33 form part of these financial statements.

Statement of financial position

For the year ended 31 December 2019

	Note	£	2019 £	£	2018 £
Current assets					
Cash at bank and in hand		27,986		33,732	
Creditors: amounts falling due within one year	4	<u>(652)</u>		<u>(1,168)</u>	
Net assets			<u>27,334</u>		<u>32,564</u>
Funds:					
Unrestricted funds	5		<u>27,334</u>		<u>32,564</u>
			<u>27,334</u>		<u>32,564</u>

The financial statements were approved by the Trustees and signed on their behalf by:

Dr M P Bosomworth, Trustee
29 May 2020

The notes on pages 32 to 33 form part of these financial statements.

Notes on the financial statements

1. Accounting policies

1.1 General information

The Association of Clinical Biochemists Benevolent Fund is a registered charity registered in England and Wales. The registered office and the principal place of the company is c/o The Association for Clinical Biochemistry and Laboratory Medicine, 130-132 Tooley Street, London, SE1 2TU. The charity's registration number is 254213.

1.2 Basis of preparation

The financial statements have been prepared to 31 December 2019 under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant notes to these financial statements. The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' ('FRS 102') (effective 1 January 2015) (Charities SORP FRS 102) and the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and Charities Act 2011.

The Association of Clinical Biochemists Benevolent Fund meets the definition of a public benefit entity under FRS 102.

The financial statements are presented in sterling and rounded to the nearest pound.

1.3 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

1.4 Income

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

1.5 Expenditure

Expenditure is accounted for on an accruals basis and has been included according to its related expense category. Where costs cannot be directly attributed to particular activities they have been allocated on a basis consistent with the use of the resources. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources.

1.6 Cash at bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of the acquisition or opening of the deposit or similar account.

1.7 Financial Instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

1.8 Assessment of going concern

After making appropriate enquiries, the Trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future. In making this decision the directors have taken into consideration the risks and uncertainties arising from the COVID-19 pandemic. For this reason they continue to adopt the going concern basis in preparing the financial statements.

1.9 Taxation

The Charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charity for UK Corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

2. Analysis of resources expended by expenditure type

	Total 2019	Total 2018
	£	£
Grants paid	5,756	4,967
Accountancy	<u>(126)</u>	<u>924</u>
	<u>5,630</u>	<u>5,891</u>

3. Trustees' remuneration

None of the Trustees received any remuneration in respect of their services, nor reimbursement of expenses during the year. The aggregate remuneration to key management personnel for the year was £nil (2018 - £nil).

4. Creditors: amounts falling due within one year

	2019	2018
	£	£
Loan from the Association for Clinical Biochemistry and Laboratory Medicine	244	244
Accruals	<u>408</u>	<u>924</u>
	<u>652</u>	<u>1,168</u>

5. Statement of funds

	Movement in funds				Balance at 31 December 2019
	Balance at 1 January 2019	Income	Expenditure	Transfers	
	£	£	£	£	£
Unrestricted funds					
General funds	32,564	400	(5,630)	-	27,334

6. Related Party Transactions

At 31 December 2019, £244 (2018: £244) was due from the charity to The Association for Clinical Biochemistry and Laboratory Medicine ('ACB'), a company in which Prof N R Anderson, Dr M P Bosomworth and Prof I S Young are directors. This balance was in relation to a loan that is repayable on demand.

During the year, the charity donated £nil (2018: £1,000) to the ACB.

C.P. STEWART MEMORIAL FUND

For the year ended 31 December 2019

Trustees	Prof N R Anderson, Chair Dr M P Bosomworth, Treasurer Mr P Newland, Secretary
Charity Numbers	269345 and SC004417
Principal Address	c/o The Association for Clinical Biochemistry and Laboratory Medicine 130-132 Tooley Street London SE1 2TU
Independent Examiner	Buzzacott LLP 130 Wood Street London EC2V 6DL
Bankers	HSBC Bank Plc 281 Chiswick High Street Chiswick London W4 4HJ

Trustees' report

The Trustees present their annual report together with the financial statements of The C P Stewart Memorial Fund ('the charity') for the year ended 31 December 2019.

The report has been prepared in accordance with Part 8 of the Charities Act 2011.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 of the attached financial statements and comply with the Charity's Deed of Trust, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice (SORP) applicable to charities preparing their financial statements in accordance with 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' ('FRS 102') effective for accounting periods commencing 1 January 2015 or later.

Structure, governance and management

Constitution

The charity is governed by a Deed of Trust dated 29 January 1974.

Method of appointment or election of Trustees

The management of the charity is the responsibility of the Trustees who are elected and co-opted under the terms of the Deed of Trust.

The Trustees meet on an ad-hoc basis to consider issues. Day to day decisions in relation to the organisation and management of the Charity are contracted to a third party.

New Trustees are appointed by the Trustees with reference to the needs of the business and the particular attributes of the individuals under consideration. Induction and training of new Trustees is conducted by the Secretary.

The Trustees who served during the year were:

Dr M P Bosomworth, Treasurer

Mr P Newland, Secretary

Prof N R Anderson, Chair (appointed 28 May 2019)

Prof I S Young, Chair (resigned 28 May 2019)

Key management personnel remuneration

The Trustees consider the board of Trustees as comprising the key management personnel of the charity in charge of directing and controlling the Charity and running and operating the charity on a day to day basis. All Trustees give their time freely and there was no Trustee remuneration or expenses paid in the year.

Policies and objectives

The principal objective of the charity is to fund the advancement of scientific knowledge and education by providing financial support to enable scientists to visit laboratories within the United Kingdom or elsewhere for the purposes of learning specialised techniques to obtain first-hand knowledge from a recognised expert in a field that would assist them in their studies.

Achievements and performance

Going concern

After making appropriate enquiries, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future.

The worldwide outbreak of the coronavirus pandemic (COVID-19) has caused extensive disruptions to organisations globally with major implications for operations as well as finances. The Trustees acknowledge and recognise the potential impact of the COVID-19, however

given that the charity has no staff, and its sole purpose is to award grants which are subject to available reserves, the Trustees continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the accounting policies.

Principal risks and uncertainties

The Trustees have reviewed all major risks to which the Charity is exposed and established systems to mitigate them. The Trustees have been aware of the Charity's dependence on the Trustees' own time and energies, voluntarily donated.

Financial review

Review of activities

The net expenditure for the year was £708 (2018 - £1,246).

Reserves policy

It is the policy of the charity to maintain unrestricted funds which are adequate to fulfill the objectives of the charity, subject to the limitations placed on the use of funds which has resulted in reserves building up to the current level.

At 31 December 2019, reserves amounted to £11,767 (2018 - £12,475). The Trustees consider the current level of reserves to be sufficient to meet the future objectives of the Charity.

Public benefit

The Trustees have given due consideration to the Charity Commission published guidance on the public benefit requirements. The Trust constitutes a public benefit entity as defined by FRS 102.

Plans for the future

Future developments

There are no plans to change the strategies employed to carry out the objective of the charity.

Trustees' responsibilities statement

The law applicable to charities in Scotland, England and Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with Financial Reporting Standard applicable in the UK and Republic of Ireland ('FRS 102');
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) the applicable Charities (Accounts and reports) regulations and the provision of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the Charity and financial information included on the Charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

This report was approved by the Trustees and signed on their behalf by:

Dr M P Bosomworth, Trustee
29 May 2020

Independent examiner's report

I report to the charity's Trustees on the accounts of the charity for the year ended 31 December 2019, which are set out on pages 36-39.

This report is made solely to the charity's Trustees, as a body, in accordance with section 44 (1) (c) of the Charities and Trustee Investment (Scotland) Act 2005 and section 145 of the Charities Act 2011 and regulations made under section 154 of the Charities Act 2011. My work has been undertaken so that I might state to the charity's Trustees those matters I am required to state to them in an independent examiner's report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the charity and the charity's Trustees, as a body, for my work or this report.

Respective responsibilities of Trustees and examiner

As the Trustees of the charity you are responsible for the preparation of the accounts, in accordance with the terms of the Charities and Trustee Investment (Scotland) Act 2005 ('the 2005 Act') and the Charities Accounts (Scotland) Regulations 2006 (as amended), and the Charities Act 2011. You are satisfied that your charity is not required by charity law to be audited and have chosen instead to have an independent examination.

I report in respect of my examination of the charity's accounts as carried out under section 44 (1) (c) of the 2005 Act and section 145 of the 2011 Act. In carrying out my examination I have followed the requirements of Regulation 11 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and the applicable directions given by the Charity Commission under 145 (5) (b) of the 2011 Act.

Independent examiner's statement

Since the charity has prepared its accounts on an accruals basis and is also registered in Scotland your examiner must be a number of a body listed in regulation 11(2) of the Charities Accounts (Scotland) Regulations 2006 (as amended). I can confirm that I am qualified to undertake the examination because I am a registered member of the ICAEW, which is one of the listed bodies.

In the course of my examination, I confirm no matter has come to my attention giving me cause to believe that in any material respect:

- accounting records were not kept in respect of the Charity as required by Section 44(1) (a) of the 2005 Act and Regulation 4 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and section 130 of the 2011 Act; or
- the accounts do not accord with those records; or
- the accounts do not comply with the accounting requirements in Regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and do not comply with the applicable requirements concerning the form and content of the accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

*Mark Worsey FCA
for and on behalf of Buzzacott LLP, London
29 May 2020*

Statement of financial activities (incorporating an income and expenditure account)

For the year ended 31 December 2019

	Note	Unrestricted Funds 2019 £	Total Funds 2019 £	Total Funds 2018 £
Income				
Investment income		—	—	<u>20</u>
Total income		<u>—</u>	<u>—</u>	<u>20</u>
Expenditure				
Charitable activities		<u>708</u>	<u>708</u>	<u>1,266</u>
Total expenditure	2	<u>708</u>	<u>708</u>	<u>1,266</u>
Net expenditure		708	708	(1,246)
Net movement in funds		(708)	(708)	(1,246)
Reconciliation of funds				
Total funds brought forward		<u>12,475</u>	<u>12,475</u>	<u>13,721</u>
Total funds carried forward		<u>11,767</u>	<u>11,767</u>	<u>12,475</u>

All gains and losses arising in the year have been included in the Statement of Financial Activities and arise from continuing operations.

The notes on pages 37 to 39 form part of these financial statements.

Statement of financial activities (incorporating an income and expenditure account)

For the year ended 31 December 2018

	Note	Unrestricted Funds 2018 £	Total Funds 2018 £	Total Funds 2017 £
Income				
Investment income		<u>20</u>	<u>20</u>	<u>35</u>
Total income		<u>20</u>	<u>20</u>	<u>35</u>
Expenditure				
Charitable activities		<u>1,266</u>	<u>1,266</u>	<u>1,145</u>
Total expenditure	2	<u>1,266</u>	<u>1,266</u>	<u>1,145</u>
Net expenditure		(1,246)	(1,246)	(1,110)
Net movement in funds		(11,289)	(11,289)	(1,110)
Reconciliation of funds				
Total funds brought forward		<u>13,721</u>	<u>13,721</u>	<u>14,831</u>
Total funds carried forward	5	<u>12,475</u>	<u>12,475</u>	<u>13,721</u>

All gains and losses arising in the year have been included in the Statement of Financial Activities and arise from continuing operations.

The notes on pages 37 to 39 form part of these financial statements.

Statement of financial position

For the year ended 31 December 2019

	Note	£	2019 £	£	2018 £
Current assets					
Cash at bank and in hand		12,175		18,631	
Creditors: amounts falling due within one year	4	<u>(408)</u>		<u>(6,156)</u>	
Net assets			<u>11,767</u>		<u>12,475</u>
Funds:					
Unrestricted funds	5		<u>11,767</u>		<u>12,475</u>
			<u>11,767</u>		<u>12,475</u>

The financial statements were approved by the Trustees and signed on their behalf by:

Dr M P Bosomworth, Trustee
29 May 2020

The notes on pages 37 to 39 form part of these financial statements.

Notes on the financial statements

1. Accounting policies

1.1 General Information

The C P Stewart Memorial Fund is a registered charity registered in Scotland and England and Wales. The registered office and the principal place of the charity is c/o The Association for Clinical Biochemistry and Laboratory Medicine, 130-132 Tooley Street, London, SE1 2TU. The charity's registration number in Scotland is SC004417 and its registered charity number in England and Wales is 269345.

1.2 Basis of preparation

The financial statements have been prepared to 31 December 2019 under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant notes to these financial statements. The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' ('FRS 102') (effective 1 January 2015) (Charities SORP FRS 102) the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended).

The C P Stewart Memorial Fund meets the definition of a public benefit entity under FRS 102.

The financial statements are presented in sterling and rounded to the nearest pound.

1.3 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

1.4 Income

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

1.5 Expenditure

Expenditure is accounted for on an accruals basis and has been included under expense categories that aggregate all costs for allocation to activities. Where costs cannot be directly attributed to particular activities they have been allocated on a basis consistent with the use of the resources. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources.

1.6 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

1.7 Cash at bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of the acquisition or opening of the deposit or similar account.

1.8 Financial Instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

1.9 Assessment of going concern

After making appropriate enquiries, the Trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future. In making this decision the directors have taken into consideration the risks and uncertainties arising from the COVID-19 pandemic. For this reason they continue to adopt the going concern basis in preparing the financial statements.

1.10 Taxation

The Charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charity for UK Corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

2. Analysis of resources expended by expenditure type

	2019	2018
	£	£
Grants paid	300	283
Accountancy costs	408	924
Other charitable costs	-	59
	<u>708</u>	<u>1,266</u>

3. Trustees' remuneration

None of the Trustees received any remuneration in respect of their services, nor reimbursement of expenses during the year. The aggregate remuneration to key management personnel for the year was £nil (2018 - £nil).

4. Creditors: amounts falling due within one year

	2019	2018
	£	£
Amounts owed to related parties	-	5,232
Accruals	408	924
	<u>408</u>	<u>6,156</u>

5. **Statement of funds**

	Balance at 1 January 2019 £	Movement in funds			Balance at 31 December 2019 £
		Income £	Expenditure £	Transfers £	
Unrestricted funds					
General funds	12,475	-	(708)	-	11,767

6. **Related Party Transactions**

During the year, the charity repaid loans totalling £5,232 (2018: £nil) to The Association for Clinical Biochemistry and Laboratory Medicine ('ACB'), a company of which Prof N R Anderson, Dr M P Bosomworth, Prof I S Young and Mr P Newland are directors. At 31 December 2019, £nil (2018:£5,232) was due to the ACB.

CLINICAL BIOCHEMISTRY CONFERENCES

For the year ended 31 December 2019

Trustees	Prof N R Anderson, Chair Dr M P Bosomworth, Treasurer Mr P Newland, Company Secretary
Charity Number	SC034004
Company Number	SC241956
Principal Address	c/o The Royal Society of Edinburgh 22-26 George Street Edinburgh EH2 2PQ
Independent Examiner	Buzzacott LLP 130 Wood Street London EC2V 6DL
Bankers	HSBC Bank Plc 281 Chiswick High Street Chiswick London W4 4HJ

Trustees' report

The Trustees present their annual report together with the financial statements of Clinical Biochemistry Conferences ('the charity') for the year ended 31 December 2019.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 of the attached financial statements and comply with the Charity's Articles of Association and Accounting and Reporting by Charities: Statement of Recommended Practice (SORP) applicable to charities preparing their financial statements in accordance with 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' ('FRS 102') effective for accounting periods commencing 1 January 2015 or later.

Structure, governance and management

Constitution

Clinical Biochemistry Conferences, which is a registered charity in Scotland, is constituted under a Memorandum of Association dated 27 November 2002. Its registered charity number is SC034004. The charity is limited by guarantee and does not have share capital.

Method of appointment or election of Trustees

The management of the charity is the responsibility of the Trustees who are elected and co-opted under the terms of the Articles of Association.

The Trustees meet on an ad-hoc basis to consider issues. Day to day decisions in relation to the organisation and management of the Charity are contracted to a third party.

New Trustees are appointed by the Trustees with reference to the needs of the business and the particular attributes of the individuals under consideration. Induction and training of new Trustees is conducted by the Company Secretary.

The Trustees who served during the year were:

Dr M P Bosomworth, Treasurer
Mr P Newland, Secretary
Prof N R Anderson, Chair (appointed 28 May 2019)
Prof I S Young, Chair (resigned 28 May 2019)

Key management personnel remuneration

The Trustees consider the board of Trustees as comprising the key management personnel of the Charity in charge of directing and controlling the Charity and running and operating the Charity on a day to day basis. All Trustees give their time freely and there was no Trustee remuneration or expenses paid in the year.

Policies and objectives

The objects of the Charity are to advance, spread and increase the knowledge, for the public benefit, of all aspects of the study of medicine concerned with clinical biochemistry and laboratory medicine and their diagnostic systems.

Achievements and performance

Going concern

After making appropriate enquiries, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future.

The worldwide outbreak of the coronavirus pandemic (COVID-19) has caused extensive disruptions to organisations globally with major implications for operations as well as finances. The Trustees acknowledge and recognise the potential impact of the COVID-19 pandemic on the future operations of the charity, its Stakeholders and on the wider society. Key areas of the company's operations that have been impacted include:

- The charity's ability to host conferences, which therefore impacts on its ability to generate both income and expenditure. The Trustees will therefore not incur any costs, unless there is certainty that income will accrue to the charity. This will ensure that any financial liabilities arising are met.

For this reason, they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the accounting policies.

Principal risks and uncertainties

The Trustees have reviewed all major risks to which the Charity is exposed and established systems to mitigate them. The Trustees have been aware of the Charity's dependence on the Trustees' own time and energies, voluntarily donated.

Financial review

Review of activities

The net expenditure for the year was £9,962 (2018 - £11,289).

Reserves policy

At 31 December 2019, reserves amounted to £66,358 (2018 - £76,320). The Trustees consider the current level of reserves to be sufficient to meet the future objectives of the Charity.

In preparing this report, the Trustees have taken advantage of the small companies exemptions provided by Section 415A of the Companies Act 2006.

Public benefit

The Trustees have given due consideration to the Charity Commission published guidance on the public benefit requirements. The Trust constitutes a public benefit entity as defined by FRS 102.

Plans for the future

Future developments

There are no plans to change the strategies employed to carry out the objective of the charitable company.

Trustees' responsibilities statement

The Trustees (who are also directors of Clinical Biochemistry Conferences for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the income and the expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with Financial Reporting Standard applicable in the UK and Republic of Ireland ('FRS 102');
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The Trustees are responsible for keeping proper accounting records that are sufficient to show and explain the charity's transactions and disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland ('FRS 102'). They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the Charity and financial information included on the Charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

This report was approved by the Trustees and signed on their behalf by:

Dr M P Bosomworth, Trustee
29 May 2020

Independent examiner’s report

I report to the charity’s Trustees on the accounts of the charity for the year ended 31 December 2019, which are set out on pages 42-45. This report is made solely to the charity’s Trustees, as a body, in accordance with section 44 (1) (c) of the Charities and Trustee Investment (Scotland) Act 2005. My work has been undertaken so that I might state to the charity’s Trustees those matters I am required to state to them in an independent examiner’s report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the charity and the charity’s Trustees, as a body, for my work or this report.

Respective responsibilities of Trustees and examiner

The Trustees (who are also the directors of the company for the purposes of company law) are responsible for the preparation of the accounts, in accordance with the terms of the Charities and Trustee Investment (Scotland) Act 2005 (‘the 2005 Act’) and the Charities Accounts (Scotland) Regulations 2006 (‘the 2006 Accounts Regulations’). The Trustees consider that the audit requirement of Regulation 10(1) (a) to (c) of the 2006 Accounts Regulations does not apply. It is my responsibility to examine the accounts as required under section 44(1) (c) of the 2005 Act and to state whether particular matters have come to my attention.

Basis of independent examiner’s report

My examination was carried out in accordance with regulation 11 of the 2006 Accounts Regulation. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosure in the accounts, and seeking explanations from you as Trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and consequently I do not express an audit opinion on the view given by the accounts.

Independent examiner’s statement

In the course of my examination, no matter has come to my attention:

- which gives me reasonable cause to believe that in any material respect the requirements to keep accounting records in accordance with Section 44(1) (a) of the 2005 Act and Regulation 4 of the 2006 Accounts Regulations; or to prepare accounts which accord with the accounting records, and comply with the accounting records and comply with Regulation 8 of the 2006 Accounts Regulations have not been met or
- to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.

*Mark Worsley FCA
for and on behalf of Buzzacott LLP, London
29 May 2020*

Statement of financial activities (incorporating an income and expenditure account)

For the year ended 31 December 2019

	Note	Unrestricted Funds 2019 £	Total Funds 2019 £	Total Funds 2018 £
Income				
Donations and legacies		—	—	—
Total income		—	—	—
Expenditure				
Charitable activities		<u>9,962</u>	<u>9,962</u>	<u>11,289</u>
Total expenditure	2	<u>9,962</u>	<u>9,962</u>	<u>11,289</u>
Net expenditure		(9,962)	(9,962)	(11,289)
Net movement in funds		(9,962)	(9,962)	(11,289)
Reconciliation of funds				
Total funds brought forward		<u>76,320</u>	<u>76,320</u>	<u>87,609</u>
Total funds carried forward		<u>66,358</u>	<u>66,358</u>	<u>76,320</u>

All gains and losses arising in the year have been included in the Statement of Financial Activities and arise from continuing operations.

The notes on pages 44 to 45 form part of these financial statements.

Statement of financial activities (incorporating an income and expenditure account)

For the year ended 31 December 2018

	Note	Unrestricted Funds 2018 £	Total Funds 2018 £	Total Funds 2017 £
Income				
Donations and legacies		—	—	—
Total income		—	—	—
Expenditure				
Charitable activities		<u>11,289</u>	<u>11,289</u>	<u>8,233</u>
Total expenditure	2	<u>11,289</u>	<u>11,289</u>	<u>8,233</u>
Net expenditure		(11,289)	(11,289)	(8,233)
Net movement in funds		(11,289)	(11,289)	(8,233)
Reconciliation of funds				
Total funds brought forward		<u>87,609</u>	<u>87,609</u>	<u>95,842</u>
Total funds carried forward	6	<u><u>76,320</u></u>	<u><u>76,320</u></u>	<u><u>87,609</u></u>

All gains and losses arising in the year have been included in the Statement of Financial Activities and arise from continuing operations.

The notes on pages 44 to 45 form part of these financial statements.

Statement of financial position

For the year ended 31 December 2019

	Note	£	2019 £	£	2018 £
Current assets					
Debtors	4	66,595		75,989	
Cash at bank and in hand		<u>171</u>		<u>865</u>	
		66,766		76,854	
Creditors: amounts falling due within one year	5	<u>(408)</u>		<u>(534)</u>	
Net assets			<u><u>66,358</u></u>		<u><u>76,320</u></u>
Funds:					
Unrestricted funds	6		<u><u>66,358</u></u>		<u><u>76,320</u></u>
			<u><u>66,358</u></u>		<u><u>76,320</u></u>

The Trustees consider that the charity is entitled to exemption from the requirement to have an audit under the provisions of section 477 of the Companies Act 2006 ('the Act') and members have not required the charity to obtain an audit for the year in question in accordance with section 476 of the Act.

The Trustees acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and for preparing financial statements which give a true and fair view of the state of affairs of the company as at 31 December 2019 and of its net expenditure for the year in accordance with the requirements of sections 394 and 395 of the Act and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charity.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements were approved by the Trustees and signed on their behalf by:

Dr M P Bosomworth, Trustee
29 May 2020

The notes on pages 44 to 45 form part of these financial statements.

Notes on the financial statements

1. Accounting policies

1.1 General information

Clinical Biochemistry Conferences is a private company limited by guarantee, and incorporated in the United Kingdom. The registered office and the principal place of the company is c/o The Royal Society of Edinburgh, 22-26 George Street, Edinburgh, EH2 2PQ. The registered number is SC241956. The company is a registered charity in Scotland and its registered charity number is SC034004.

1.2 Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' ('FRS 102') (effective 1 January 2015) (Charities SORP FRS 102) the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended).

Clinical Biochemistry Conferences meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The financial statements are presented in sterling and rounded to the nearest pound.

1.3 Company status

The charitable company is incorporated as a company limited by guarantee. The members of the company are the Trustees named on page 40. In the event of the company being wound up, the liability in respect of the guarantee is limited to £1 per member of the company.

1.4 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

1.5 Income

Donations are recognised when the Charity has confirmation of both the amount and settlement date. In the event of donations pledged but not received, the amount is accrued for where the receipt is considered probable. In the event that a donation is subject to conditions that require a level of performance before the Charity is entitled to the funds, the income is deferred.

1.6 Expenditure

Expenditure is accounted for on an accruals basis and has been included under expense categories that aggregate all costs for allocation to activities. Where costs cannot be directly attributed to particular activities they have been allocated on a basis consistent with the use of the resources.

Support costs are those incurred directly in support of expenditure on the objects of the Charity. Governance costs are those incurred in connection with administration of the company and compliance with constitutional and statutory requirements.

1.7 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.8 Cash at bank and in hand

Cash is represented by deposits held with financial institutions repayable without penalty on notice of not more than 24 hours.

1.9 Financial Investments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

1.10 Assessment of going concern

After making appropriate enquiries, the Trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future. In making this decision the directors have taken into consideration the risks and uncertainties arising from the COVID-19 pandemic. For this reason they continue to adopt the going concern basis in preparing the financial statements.

1.11 Taxation

The Charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charity for UK Corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

2. Analysis of resources expended by expenditure type

	2019	2018
	£	£
Charitable activities	9,141	10,383
Support costs	<u>821</u>	<u>906</u>
	<u><u>9,962</u></u>	<u><u>11,289</u></u>

3. Employees and staff costs

The average head count of employees during the year was:

	2019	2018
	Number	Number
Management	<u>3</u>	<u>3</u>
	<u>3</u>	<u>3</u>

None of the Trustees received any remuneration in respect of their services, nor reimbursement of expenses during the year. The aggregate remuneration to key management personnel for the year was £nil (2018 - £nil).

4. Debtors

	2019	2018
	£	£
Amounts owed by group undertakings – unrestricted funds	<u>66,595</u>	<u>75,989</u>

5. Creditors: amounts falling due within one year

	2019	2018
	£	£
Accruals – unrestricted funds	<u>408</u>	<u>534</u>

6. Statement of funds

	Balance at 1 January 2019	Movement in funds			Balance at 31 December 2019
		Income	Expenditure	Transfers	
	£	£	£	£	£
Unrestricted funds					
General funds	76,320	-	(9,962)	-	66,358

7. Related Party Transactions

The charity is a subsidiary of the Association for Clinical Biochemistry and Laboratory Medicine ('ACB') by virtue of common control. All Trustees of CBC are also directors of ACB.

During the year ACB paid expenses on behalf of CBC totalling £7,394 (2018 - £7,474) and repaid £2,000 (2018 - £4,500) in respect of the loan between ACB and the Charity. At 31 December 2019 £66,595 (2018 - £75,989) was due from ACB to the charity.

ACKNOWLEDGEMENTS

We would like to thank all committee and sub-committee members who manage to combine their ACB roles alongside their day-to-day responsibilities. Below we list special thanks to individuals as requested by Committee Chairs and Directors.

Education, Training and Workforce Committee

Special thanks to:

- ◆ Professor John Geen who was the Welsh Regional Tutor and sat on the Education Committee for nearly 12 years. His expertise and guidance were very much appreciated throughout his extended term.
- ◆ Dr Donna Fullerton for her role as Lead Station Writer within the NSHCS. Her dedication to Education is unrivalled and she has led the development of many new OSFA stations this year.
- ◆ Dr Emma Walker for her role in co-ordinating the ACB Management Course. This is a highly successful course that could not go ahead without her leadership.

Scientific Committee

Special thanks to:

- ◆ Dr Chris Chaloner, for his twelve years as part of the Scientific Committee, including five years as Chair.
- ◆ Dr Mayur Patel, who has joined as Director of Clinical Practice since merging the Scientific Committee and the Clinical Practice Section.
- ◆ Dr Owen Driskell, for his work acting as a link between ACB and the NICE Diagnostic Advisory Committee where he is also a standing member.
- ◆ New Members Miss Anna Barton and Mrs Shonagh Haslam as Ordinary Members, and Mr Gordon Avery as Corporate Member.
- ◆ The peer reviewers that appraise the ACB Scientific Scholarships before consideration by the Scientific Committee.
- ◆ Dr Sodi, Mr Davidson and Ms Garrison, who have stepped down from the CSRC.
- ◆ The new AMALC Editor, Gina Fredrick.
- ◆ ACB NICE subcommittee's review of NICE outputs.

Publications Committee

Special thanks to:

- ◆ The ACB office for their hard work supporting the Committee.
- ◆ The *ACB News* team for producing the *ACB News* magazine to tight deadlines.
- ◆ Jane Pritchard, ACB CEO, for overseeing the ACB's communications projects.
- ◆ Agnes Becker, Freelance Science Communications Consultant, for her work streamlining the ACB social media accounts and input into the ACB communications outputs.
- ◆ Sarah Sewell who stepped down as Production Editor from SAGE (*Annals'* publisher) and welcome to her replacement, Kiran Yadav.

- ◆ Maurice O'Kane for commissioning a steady supply of high-quality editorials for *Annals*.

Welcome to:

- ◆ Dr Joanne Adaway, Dr Michael Page, Dr Roy Peake and Dr Rav Sodi, joining as *Annals'* Associate Editors.
- ◆ Dr Melanie Percy, who is back from sabbatical.
- ◆ Jenny Nobes and Ceri Parfitt as new Social Media Editors for *Annals*.

National Meetings Committee

Special thanks to:

- ◆ Kathryn Brownbill, David Clark and Gwyn McCreanor for their continued support with the organisation of FiLM and to Graham Lee for joining the committee this year.
- ◆ Robert Michel for his work organising the Frontiers in Laboratory Medicine (FiLM) meetings over the years. Robert will still support the meeting and the Executive War College Conference on Laboratory and Pathology Management Bursary, but will no longer be actively involved with organising FiLM.

Microbiology Professional Committee

Special thanks to:

- ◆ Committee members Dr Derren Ready and Dr Zoie Aiken, who continue to improve the Objective Structured Final Assessment process.
- ◆ Dr Naomi Gadsby, for her hard work in organising annual meetings.
- ◆ All Members, including Dr Kate Templeton, who continue to be involved in the Scientific Training Programme equivalence process and with assessing Higher Specialist Scientific equivalence via the Academy for Healthcare Science.
- ◆ Dr Kate Templeton and Dr Kirsty Dodgson, who represent our interests at the Royal College of Pathologists.
- ◆ Victoria Miari, who is now Deputy Director for Affairs.
- ◆ Dr Elaine Cloutman-Green, who co-ordinates our *ACB News* content and Dr Mathew Diggle for the always thought provoking Diggle's Challenge.
- ◆ Dr Penny Cliff, who is working hard with the ACB team on the much-needed website upgrade.

Federation of Clinical Scientists

Special thanks to:

- ◆ Geoff Lester, who is standing down as the National Negotiator Lead for FCS to take on a role looking at pension issues. He continues to link in with colleagues in Public Health England.

- ◆ Mike Cornes, who has taken on the role of National Negotiator.
- ◆ ACB office staff for all their help and support during the year; it makes the lives of the Officers much easier and allows us to fulfil our roles.
- ◆ Our Chartered Society of Physiotherapy industrial relations representative, Emma Lenehan, for all her help and invaluable advice.
- ◆ Local and regional representatives who find time in their busy schedules to support FCS and its work. The FCS relies on its local and regional representatives to carry out its work and provide information to its members locally.

Director of Finance

Special thanks to:

- ◆ ACB staff for their continued hard work and commitment to our Association.
- ◆ Fellow members of ACB Council and Executive.
- ◆ Regional committees and officers and our regional and National Meetings organisers for their immense contribution to the Association.

Regional Committees

North West Region Committee

Special thanks to:

- ◆ Jane Oakey, who stepped down as Secretary/Treasurer after three years of dedication and hard work in this dual role.
- ◆ Charlotte Harborow, whose three years as an Ordinary Member also finished at this AGM.
- ◆ Suzy Armitage, who has agreed to take on the role of Meetings Secretary (in addition to the Workforce Advisor role), for one year in the first instance.
- ◆ Everyone who has been part of the Committee in 2019, and has contributed to the activities of the North West Region.

Northern Ireland Region Committee

Special thanks to:

- ◆ Dr Kathryn Ryan, for organising the Annual Scientific Meeting and for serving as Meeting Secretary for three years.
- ◆ Dr Derek McKillop, for his work developing the Disease Detective pack for Cub Scouts.

Southern Region Committee

Special thanks to:

- ◆ Our commercial sponsors.
- ◆ Sally Benton, Ruth Ayling and Alex Read, for organising the Annual 2019 meeting.

- ◆ ACB office for their help in organising our various meetings throughout the year.
- ◆ Peter West, Chair of the Thames Clinical Biochemistry Audit group and Funmi Akinlade, Dawn Grenshaw, Sabrina Mosaheb and Nikola Costa for organising two successful Audit Meetings.
- ◆ Southern Region FCS representatives.

South West and Wessex Region Committee

Special thanks to:

- ◆ Anthea Patterson, for writing the Annual Report.
- ◆ Previous Committee members.

Trent and Northern Yorkshire Region Committee

Special thanks to:

- ◆ Nuthar Jassam, for organising the Spring Scientific Meeting in Harrogate.
- ◆ Stephen Gibbons, for organising and Carys Lippiatt for chairing the Autumn/Winter Scientific Meeting in Leeds.
- ◆ Julian Barth, who retired in November.
- ◆ Deepa Narayanan, for chairing the first Regional Audit Meeting.
- ◆ Previous Chair, Nuthar Jassam.
- ◆ Previous Committee members: Adrian Miller, Regional Tutor (Yorkshire); Chris Holmes, Microbiology Representative; Tim Lang, Regional Tutor (Northern); Abigail Williams, Trainees' Committee Representative (Trent); and Liz Middling, FCS Representative (Northern).

Wales Region Committee

Special thanks to:

- ◆ Dr Anthony Jackson-Crawford, for organising, and Betsi Cadwaladr, BCUHB University Health Board for supporting the ACB Wales Autumn Scientific Meeting in November 2019.
- ◆ Dr David Cassidy, on his retirement, and with congratulations for his ACB Emeritus membership.
- ◆ Outgoing Committee members: Professor John Geen (Chair and Regional Tutor), Mr Gareth Davies (Webmaster), Mrs Julia Walsh (Ordinary Member) and Dr Joanna Flatt (Trainees' Representative) for all their commitment and hard work over the years.
- ◆ Our meeting sponsors.

West Midlands Region Committee

Special thanks and welcome to everyone on the recently re-established regional committee.

President

Dr N R Anderson *BSc MSc PhD CSci FRCPath EuSpLM*
Dept of Clinical Biochemistry
University Hospitals Coventry & Warwickshire NHS Trust
Clifford Bridge Road
Coventry CV2 2DX

Chief Executive Officer

Jane Pritchard
Association for Clinical Biochemistry & Laboratory Medicine
130-132 Tooley Street
London SE1 2TU

Honorary Secretary

Mr P Newland *BSc MPhil FRCPath EuSpLM*
Dept of Clinical Biochemistry
2nd Mezzanine Level, HB
Al Luqta Street
PO Box 26999
Doha
Qatar

Administrative Office

Association for Clinical Biochemistry & Laboratory Medicine
130-132 Tooley Street
London SE1 2TU
Tel: 020 7403 8001
Fax: 020 7403 8006
Email: enquiries@acb.org.uk

Registered Office

Association for Clinical Biochemistry & Laboratory Medicine
130-132 Tooley Street
London SE1 2TU

Social Media

ACB Twitter:	 @TheACBNews
ACB Facebook:	 facebook.com/AssocClinBioLabMed
Annals of Clinical Biochemistry:	 @AnnClinBiochem
Lab Tests Online-UK:	 @LabTestsUK
Scientific Committee:	 @SciCom_odo
Microbiology Professional Committee:	 @TheACBNews using #ACBMicro

Coordinated by Agnes Becker

Infographics by Agnes Becker

Edited by Sophie Gillespie

Proofread by Brendan O'Brien

Layout by Nikki Williams, Cambridge



**The Association for
Clinical Biochemistry &
Laboratory Medicine**

Better Science, Better Testing, Better Care

The Association for Clinical Biochemistry and Laboratory Medicine (ACB)
is the professional body dedicated to the practice and promotion of
Clinical Biochemistry, Immunology and Microbiology in the UK

Association for Clinical Biochemistry & Laboratory Medicine

130-132 Tooley Street

London SE1 2TU

Tel: 020 7403 800

Website: www.acb.org.uk